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EVALUATION OF NOVEL THERAPEUTICS FOR HIV PREVENTION AND 
TREATMENT IN A HUMANIZED MOUSE MODEL 
 
In the absence of an effective HIV-1 vaccine finding alternative therapeutics and 
preventative methods has become essential. In this regard preventative approaches such 
as pre-exposure chemo-prophylaxis that employ either topical applied microbicides or 
systemically administered anti-retroviral drugs show great promise. In these studies, we 
evaluated two new classes of clinically approved drugs with different modes of action 
namely, an integrase inhibitor raltegravir and a CCR5 inhibitor maraviroc as potential 
systemically and topically applied pre-exposure chemo-prophylaxis. Additionally, 
therapeutic strategies designed to combat HIV/AIDS using siRNAs show considerable 
promise. However, targeted delivery of these synthetic molecules into infected cells in 
vivo has been a formidable challenge. In addressing this need we sought to evaluate the 
efficacy of a chimeric construct consisting of an HIV-1 gp120 specific aptamer with viral 
neutralization capacity fused to a siRNA with proven efficacy against tat/rev viral 
transcripts.  We also sought to evaluate the efficacy of structurally flexible, cationic 
PAMAM dendrimers as a siRNA delivery system. 


For these novel therapeutic strategies to succeed it is important to evaluate them 
in both in vitro and in vivo. The rhesus macaque has been a valuable research tool for 
comparative HIV-1 studies. However, aspects of this model render its usefulness limited 
considering its expensive nature and not utilizing HIV-1 itself.  In this regard the recently 
developed humanized mouse model that permits multi-lineage human hematopoiesis is an 
excellent alternative to the non human primate model. To generate humanized mice, 
neonatal Rag2-/-c-/- or Rag1-/-c-/- mice were xenografted with human CD34+ 
hematopoietic stem cells, resulting in a model that can permit HIV-1 infection. Upon 
infection by HIV-1 chronic viremia develops with a subsequent loss of CD4 T cells. 
These mice also successfully mimic the predominant mode of HIV-1 transmission via the 
sexual vaginal route which also results in chronic viremia and helper T cell loss. Thus 
this small animal model permits the rapid preclinical evaluation of potential candidates 
for pre-exposure prophylactic (PrEP) efficacy as well as novel RNA-based therapeutics.   
Here we utilize these humanized mouse models to evaluate the PrEP efficacies of 
the drugs named above as well as the in vivo efficacy of siRNAs delivered by utilizing a 
chimeric aptamer construct or a PAMAM dendrimer.  Our results showed that both of 
these approaches using either a chimeric aptamer or a PAMAM dendrimer resulted in 
suppression of viral loads in vivo and most importantly also resulted in protection from T-
cell depletion, making these compounds attractive therapeutic candidates for the 
treatment of HIV-1 infection. Lastly, using the same humanized mouse model we also 
successfully tested a gene therapy strategy employing lentiviral vectors having RNA-
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OVERVIEW OF LITERATURE 
 
 
In 1981, the first recognized case of acquired immunodeficiency syndrome 
(AIDS) was reported by the Centers for Disease Control and Prevention (CDC) (1).  
Shortly after this first AIDS case was recognized, the causative agent was discovered to 
be of viral origin. The virus was isolated from the lymph node of a patient with 
lymphadenopathy at the Pasteur Institute in Paris. The following year researchers at the 
U.S. National Institutes of Health and at the University of California independently found 
cytophatic, T-cell-tropic retroviruses from blood cells of AIDS patients (2). 
Soon after individual isolates of the virus were examined by electron microscopy, 
it was apparent that this AIDS causing virus was morphologically similar to the 
lentiviruses, a group of retroviruses with the characteristic of slow disease progression 
and long incubation periods. In 1986 under the recommendation of the International 
Committee on Taxonomy of Viruses the causative was named Human Immunodeficiency 
Virus (HIV-1).   
Following the discovery of HIV-1, screening tests were developed for diagnosis 
of infected individuals. Once large scale testing became available the global impact of 
HIV became apparent (2). According to the Joint United Nations Programme on


 HIV/AIDS (UNAIDS) in January 2010 more than 35 million people worldwide 
are living with HIV/AIDS. With current estimates to be about 0.6 percent of the world’s 
population living with HIV-1, this virus has grown to a global pandemic scale in need of 
urgent and immediate attention.   
 
1.1 Structural Organization of HIV-1 
An HIV virion is spherical in shape with a diameter of about 120nm (3). The virus 
consists of two copies of positive single-stranded RNAs that code for the viral genes. 
HIV-1 is enclosed by a capsid comprised of the viral protein p24 (4). Like all 
retroviruses, HIV-1 has two layers of phospholipids that form the viral envelope. The 
envelope (Env) protein is comprised of glycoprotiens (gp), specifically, a cap, gp120, and 
a stem, gp41. These glycoproteins seen as “spikes” on the viral surface are used for 
selective binding to CD4 T cells (5). 
The single stranded RNA genome of HIV has seven distinct regions. These 
include the long terminal repeat (LTR), trans-activation response (TAR) element, rev 
response element (RRE), psi element (PE), a poly(T) slippery site (SLIP), cis-acting 
response sequences (CRS) and the inhibitory RNA sequence (INS) (4, 5) (Figure 1.1).  
The LTR is responsible for the incorporation of retroviral DNA genetic sequences into 
host genomes and also acts as a transcription promoter. TAR is required for the trans-
activation of the viral promoter as well as acting as a binding site for the transactivator of 
transcription (Tat) protein to activate the LTR. RRE is used as a binding site by the 
regulator of virion expression (Rev) protein to stabilize, export and shuttle the unspliced 
RNA from the nucleus to the cytoplasm. PE required for packaging of the viral genome. 


SLIP is a poly(T) element that by encoding a T repeat causes a frame shift in the group 
specific antigen (Gag) reading frame into the polymerase (Pol) reading frame (4, 5) 
(Figure 1.1).  
Figure 1.1 Schematic representation of the HIV genome including genes and genomic elements. 
 
HIV-1 has nine genes including env, gag, pol, nef, rev, tat, vif, vpr, and vpu (4, 5) 
(Figure 1.1). As addressed above, the env gene is essential for production of gp160 
protein (4-6). Gag (along with env) encode for the structural proteins of new virons. Pol 
codes for three essential enzymes: reverse transcriptase, integrase and HIV-1 protease. 
The negative factor (Nef) is involved in down regulating the CD4 receptor and the major 
histocompatibilty complex (MHC) molecules in infected cells, thus masking them from 
attack by the immune system (5-8). The rev gene encodes Rev protein. Tat encodes two 
Tat proteins that act as transcriptional transactivators for the LTR promoter by binding to 
TAR (9). Viral infectivity factor (Vif) protein is used to prevent the apolipoprotein B 
mRNA editing enzyme, catalytic polypeptide-like protein (APOBEC) from deaminating 
DNA:RNA hybrids, specifically important because of its interference with Pol protein (4, 
5). Viral protein R (Vpr) and viral protein U (Vpu) are other regulators of the virus and 

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are associated with infectivity (5). Gag, Pol, and Env are common to all retrovriuses. Tat 
and Rev are essential for HIV replication (4, 5). The remaining genes are not essential for 
viral production in immortalized T-cell lines and are thus classified as accessory proteins. 
 
1.2 HIV Viral Tropism 
All strains of HIV-1 infect CD4+ cells; however, different isolates require distinct 
secondary coreceptors to undergo productive fusion and entry. HIV-1 entry is mediated 
by initial binding of virion envelope glycoprotein, gp120, with the CD4 molecule and 
gp41 with a chemokine coreceptor (CCR5 or CXCR4 mostly) (6). CD4 is a member of 
the immunoglobulin superfamily while the chemokine coreceptors are 7-transmembrane 
G-protein coupled receptors. HIV-1 virus that utilizes CCR5 (HIV-1 R5 or macrophage- 
tropic) is considered to be primary (10). There are also dual tropic variants that can 
recognize both CCR5 and CXCR4 (HIV-1 X4R5). Marcrophages, which also express 
CCR5 and CXCR4, are assumed to be the first cells infected by HIV-1 and the last ones 
to harbor the virus after CD4 T cell depletion (6). There are also cells that do not express 
CD4 but are infected by HIV-1 including dendritic cells, and microglial cells which 
express CCR3 and/or CXCR4 (11).   
Entry into the cell begins after CD4 and a chemokine receptor have been bound 
by the trimeric envelope complex (gp120). Upon binding with gp120, integrin is 
activated allowing for virological synapses, which mediates virus infection (6). With 
high-affinity binding of CD4 to gp120 the envelope undergoes structural changes to 
expose the chemokine binding domains of gp120 allowing them to bind with the 

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chemokine coreceptor.  Gp41 is then used to penetrate the cell membrane allowing for 
entry of the viral capsid (6). 
 
1.3 HIV Viral Genome Replication 
After membrane fusion and upon partial disassemble of the capsid, viral enzymes 
and RNA are released into the cell. Microtubules are utilized for transport of the viral 
RNA as a complex to the nucleus (12). During transport, reverse transcriptase (RT) 
removes the RNA from the bound viral proteins and reverse transcribes it into DNA. 
After the first DNA strand is formed RT uses ribonuclease activity to degrade the viral 
RNA and finally acts as DNA-dependent DNA polymerase and replicates the sense DNA 
strand into an antisense DNA forming partial double stranded complementary DNA 
(cDNA) (12). This cDNA is directed by LTR binding and integrated into the host 
chromosome by integrase (13). 
When viral mRNA is transcribed it is spliced into smaller pieces which are 
exported to the cytoplasm and translated into regulatory proteins Tat and Rev (4, 5). With 
Tat protein new virus production is encouraged and meditaion of elongation of viral RNA 
occurs. Tat binds to the Tar RNA region that forms a stable stem-loop structure (9). Rev 
protein helps with viral RNA export from the nucleus, and allows unspliced RNAs to 
leave the nucleus. This cycle leads to a shift in viral gene expression, underlining the 
importance of, Rev as a facilitator for the timing of viral protein and enzyme synthesis 
(14). In the cytoplasm Gag and Env are translated from full length viral mRNAs. With 




1.4 Accessory Proteins 
During infection of immortalized T-cell lines by HIV-1, a number of genes are 
not essential for viral production. These “non-essential” genes code for what are known 
as accessory proteins. Of these, Nef protein held particular focus as a high potential target 
for HIV regulation (7). There are two forms of Nef protein translated from early 
transcripts that are produced by two initial codons on the 5’ end of the Nef mRNA (4-6). 
Each protein has several post translational modifications that cause them to vary in size 
from 24 to 27 kDa. Nef proteins have protein-protein (SH3) interaction domains that can 
mediate interactions with parts of the intracellular signaling pathways. This may provide 
an optimal environment for viral replication (15). The functions of Nef protein vary for 
different strains of virus and with different types of cells (7).  It has been shown that Nef 
can down regulate surface expression of CD4, MHC class I molecules, as well as the 
immune costimulatory protein CD28 (8). This down regulation of surface expression may 
be a contributing factor for HIV-1 to evade typical host mediated viral removal leading to 
HIV-1 pathogenesis. In addition, Nef is packaged into new virions and enhances fusion 
of the viral envelope with the host cell membrane (7).   
Later in infection full length transcripts are exported to the cytoplasm, allowing 
for the production of viral infectivity factor (vif), viral protein R (vpr) and viral protein U 
(vpu) from unspliced RNA (5). The Vif protein remains mostly in the cytoplasm and the 
plasma membrane of infected cells (16). It was shown in early HIV-1 studies that the 
mutant viruses without Vif were around a thousand times less infectious than wild type 
virus (16). Recent work has shown that Vif plays a role in inhibiting the antiviral action 
of CEM15/APOBEC3G, a cellular cytidine deaminase (16, 17). This enzyme catalyzes 

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the deamination of deoxycytidine (dC) to form deoxyuridine (dU) destroying the coding 
and replicating ability of HIV-1.  
Vpr affects the rapidity of the virus to replicate in and destroy T cells (7). The 
functions for Vpr are induction of G2 cell cycle arrest and promotion of viral entry into 
the nucleus. It is unknown why G2 arrest is beneficial for virus production but is 
potentially associated with LTR activity. Lastly, Vpr was shown to bind nuclear pore 
proteins that may facilitate docking of the HIV-1 preintegration complex (7).  
In HIV-1 and SIV, Vpu is required for proper maturation of progeny virions and 
their release (18). Without this protein, virions can contain multiple cores and budding is 
to intracellular vacuolar compartments rather than the plasma membrane.  
 
1.5 HIV Viral Assembly and Budding 
Assembly of new HIV-1 virons occurs at the plasma membrane of the host cell. 
The Env polyprotein (gp160) passes through the endoplasmic reticulum and is 
transported to the golgi complex where it is cleaved by protease into two HIV envelope 
glycoproteins gp41 and gp120 (6). These glycoproteins are transported to the plasma 
membrane where gp41 anchors gp120 to the membrane of the infected cell. Maturation 
occurs in the forming bud or in the immature virion after it buds. During this process 
HIV-1 proteases cleave polyproteins into individual functional HIV-1 proteins and 






1.6 Viral Transmission 
HIV is primarily acquired through unprotected sexual encounters via contacts of 
infected body fluids to the mucosal membranes of the other. The rate of transmission 
from female-to-male is 0.04% and from male-to-female is 0.08% per act, while the rate 
for receptive anal intercourse is 1.7% (19). These percentages can be much higher in low-
income countries for many various reasons, including potential predisposing conditions 
such as genital ulcerations. The use of latex condoms can reduce the risk of sexual 
transmission of HIV by nearly 85% (20). However, the consistent use of condoms is 
limited by supply due to economic unavailability, belief systems and practices.   
The transmission efficiency of HIV-1 varies during the course of infection and is 
not consistent between individuals. However, each one log increase in viral level of HIV 
in the blood is associated with a drastic increase in rate of transmission (21). Women 
have a higher susceptibility to HIV-1 infection due to hormonal changes, vaginal 
microbial ecology and physiology as well as a higher prevalence of sexually transmitted 
diseases (21).   
 
1.7 AIDS 
Once a patient is infected with HIV-1, the virus progressively depletes immune 
cells leading to AIDS and leaves individuals susceptible to opportunistic infections and 
tumors (22). The primary characterization of AIDS is depletion of CD4+ T cells to a level 
of 200 cells or less per mm3 of blood, a 1000 fold difference from normal baseline levels 
(23). CD4 T cells are essential for establishing and maintaining the immune system. The 
loss of these cells occurs most abundantly during the acute phase of infection when HIV-

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1 causes induced cell lysis and cytotoxic T cells target and kill infected cells. T cell 
population is gradually decreased as the ability of the immune system to generate and 
replenish cells is diminished causing viral mediated T cell loss to surpass production (23). 
Most CD4+ T cell loss happens during the first weeks of infection, particularly in tissues 
such Peyer’s patches of intestinal mucosa which have high numbers of lymphocytes. 
Cells in intestinal mucosa additionally have a much higher expression of CCR5 
coreceptor compared to the T cells of blood making them more susceptible to HIV-1 
infection (22). Even with this large loss of CD4+ T cells, infected subjects usually remain 
subclinical for years after initial infection.    
AIDS has very mild symptoms caused by the disease itself, usually limited to 
non-specific conditions such as fever, sweats, chills, weakness and weight lost (24). The 
associated indications of AIDS are therefore primarily caused by opportunistic infections 
from bacteria, viruses and fungi that would normally be controlled or eliminated by a 
competent immune system (24). These infections are common in people with AIDS and 
can infect almost every organ system allowing even simple infections to be life 
threatening. AIDS has also been associated with an increased risk of cancer development. 
Cancers that arise from immune cells, such as lymphomas, are specifically more common 
in AIDS patients (25).   
Without treatment the median time of progression from HIV-1 infection to AIDS 
is nine years. The survival time after development of AIDS is 9.2 months (26). The rate 
of progression can be affected by many factors, including the body’s ability to defend 




1.8 HIV latent reservoir 
With current treatment by highly active antiretroviral therapy (HAART), many 
people are able to achieve suppressed HIV viral levels below the limit of detection for 
many years (13). However, with current drug regimens HIV is not completely eradicated, 
as seen when HIV viral loads rebound after withdrawal of HAART. Due to the 
integration of HIV into the genome of infected cells, and with its primary target being T 
cells which can function as long lasting memory cells, HIV-1 can remain dormant for 
years (13). The latent reservoir can be measured by co-culturing CD4+ T cells from 
infected patients with susceptible cells in vitro and measuring the levels of HIV-1 protein 
or RNA. This aspect of HIV-1 is most challengeing when developing an effective 
treatment against infection. 
 
1.9 Animal Models for HIV Research 
The fact that HIV-1 does not infect and cause disease in any species other than in 
humans is problematic for the process of evaluating compounds, especially vaccines and 
preventative therapeutics (27). In the initial years of HIV-1 research an animal model that 
was suitable for efficiently predicting drug efficacy in humans was not available. 
Preliminary testing with nonhuman primates and their species specific lentivirus (SIV) 
was able to recapitulate the modes of infection, disease course and antiviral immunity 
that are seen in HIV-1 infections of humans (27). The nonhuman primate model has been 
essential in understanding the key aspects of lentiviral disease. However, many aspects of 
this model render its usefulness limited. First, although very similar to humans, the 
macaque immune system has species specific cell receptors that render HIV-1 itself 

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unable to cause and sustain infection (28). Utilizing SIV as a substitute for HIV-1 allows 
for similar retroviral experimentation but lacks the complexities and specifics of HIV-1. 
Additionally, various strains including drug resistant and mutant strains of HIV-1 cannot 
be evaluated in this model. The macaque model was utilized for the first vaccine 
development for HIV-1; however, after a phase III trial in humans failed, the model was 
unable to validate any vaccine candidate (29). Additionally, the large size of the monkey 
model makes it expensive, limiting its potential for evaluating a broad range of 
compounds. With the lack of a model to fully recapitulate infection and efficacious 
effects of vaccines or preventative therapeutics it was originally speculated that 
prophylactic approaches would solely be limited to human phase I trials (29). 
The smallest available natural model for the study of lentivirus infections is the 
cat with feline immunodificency virus (FIV). FIV has a number of similarities with HIV-
1 including viral structure, induced pathology and transmission (30). Like HIV-1 the 
primary characteristic of infection is CD4+ T cell decline. However, FIV also infects B 
cells and some sub populations of CD8+ T cells (31-33). As with AIDS in humans, the 
cause of death in FIV infected cats is opportunistic infection.   
With these similarities this model has been a useful tool for parallel studies of 
HIV infection, particularly in immunological similarties that occur in the course of both 
these lentivirus infections. Additionally, due to the commonalities of HIV-1 and FIV in 
replication and multiple genome structures, FIV infection in the cat serves as a model for 
drug design (34). However, there are differences in FIV and HIV-1, including FIV 
lacking some of the HIV-1 acessory proteins, different viral envelopes and the repertoire 

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of infected cells. These differences may limit the predictability for efficacy of HIV-1 
specific drugs. 
For these reasons the development of a humanized model that replicates a human 
immune system is required for detailed pre-clinical testing. The recently developed 
humanized mouse has been effectively able to reproduce a human immune system that is 
susceptible to HIV-1 infection.  
 
1.10 Humanized Mice 
To utilize pluripotent hemopoietic stem cells (HSC) to their full potential requires 
a recipient capable of being repopulated for a hemopoietic system with complete multi-
lineage hemopoieses.  Additionally, it would be advantageous if the system could sustain 
such a long-term engraftment. The use of HSC in vivo is most appropariate for the small 
animal model given their small size and cheaper costs. With the use of small animal 
models rapid evaluation can be conducted drastically reducing the time frame for 
experimental observations.   
The first humanized mice were produced by injection of human stem cells in 
irradiated mice (35-38). These studies, although successful, only displayed low 
engraftment levels. To enhance transplantation success, knock-outs in genes important in 
development of the immunce system, including Hfh11nu and Prkdcscid, were utilized to 
develop immune-compromised models (38-41). Prkdc, or protein kinase DNA activated 
catalytic polypeptide, was identified as an essential catalytic subunit of a DNA 
recombinase enzyme that is disrupted by the scid allele. With Prkdcscid the gene has a 
nonsense mutation (42).  This scid mutation was first observed in BALB/c mice in 1983 

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and displayed engraftment of human peripheral blood mononuclear cells (PBMC) (43, 
44).  Mice homozygous for the scid mutation are unable to express rearranged antigen 
receptors resulting in lack of mature host T and B lymphocytes (43, 44). However, some 
antigen receptor rearrangements do still spontaneously occur and have been termed as 
“leakiness” (45). 
After successful production of the scid mouse, human fetal liver or fetal bone 
marrow cells were injected hepatically in unirradiated pups (46). The human cells 
survived and maintained many of the characteristics of normal human marrow in the scid 
host. A number of investigators utilized this SCID-hu model for various studies, 
including human gene therapy protocols (47, 48), and human immunological assays (49). 
However, even with these advances peripheral engraftment remained low, only 0.5-5% 
(50). Additionally, the human cell populations failed to utilize many of the murine 
hemopoietic growth factors, failing to develop adequate cell proliferation and 
differentiation. It was also assumed that competition with host cells may be the cause for 
the limited engraftment levels (50).  
To increase the stability of xeno-engraftment, these mice were crossed with non-
obese diabetic (NOD) mice to generate the NOD-SCID model (51, 52). Further 
knockouts in the interleukin receptor common gamma chain and recombination activating 
genes has given rise to the newer generation of humanized NOD-SCID-/-c-/- (hNOG) and 
Rag2-/-c-/- (RAG-hu) mouse models (53, 54). The common gamma chain, c, is a 
cytokine receptor sub-unit and is important in the formation of functional cytokine 
receptors on lymphocytes. The recombination activating gene (RAG) encodes enzymes 
that are essential for the rearrangement and recombination of the genes encoding T cell 

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receptors during VDJ recombination (54). These developments promote engraftment of 
foreign tissue, especially human hematopoietic CD34+ stem cells. RAG-hu and hNOG 
mice are prepared by injecting either cord blood or fetal liver derived CD34+ cells 
hepatically, which give rise to multilineage human hematopoiesis (53, 54) (Figure 1.2). 
These models have higher human engraftment levels which are sustained for more than a 
year (55). These mice are susceptible to HIV-1 and thus HIV can be used as the challenge 
virus directly (56). Furthermore, these mice are susceptible to vaginal and rectal HIV-1 
transmission (57, 58). Additionally, advancement with the NOD-SCID model by 
transplantation of thymic and liver tissues under the kidney capsule followed by hepatic 
injection of autologous human CD34+ cells has led to the BLT (Blood, Liver, Thymus) 
mouse model (59-60). This model shows the highest levels of human engraftment 
including substantial T cell development; however, due to its design it requires extensive 
labor and manipulation resulting in limited production and higher cost.  
 
Figure 1.2 Humanized RAG-hu mice. Neonatal mice were irradiated and injected intrahepatically with FL CD34 
cells. Ten to twelve weeks later, peripheral blood was collected and the cells were subjected to FACS analysis by 
staining for CD45 to determine human cell engraftment.  Engraftment level in a representative mouse is shown.   

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1.11 HIV Vaccine 
Almost since the time of HIV discovery the pursuit of an HIV-1 vaccine has been 
ongoing (61). Even with the advent of novel vector-based DNA vaccine designs, clinical 
trials have resulted in little protective efficacy, with the RV 144 Thailand trial providing 
the most positive, though modest, results to date (62, 63). HIV-1 vaccine design has been 
limited by the viruses' propensity for mutation, which is driven by the absence of 
corrective mechanisms during reverse transcription. Thus, even when a protective 
adaptive immune response can be developed, viral evolution is able to circumvent both 
antibody and cytotoxic defenses, allowing escape mutants to infect newly proliferating 
CD4+ T cells and further damage the already weakened immune system. 
HIV vaccine development has also been limited by lack of a defined protective 
immunity. Research thus far indicates that the cellular mediated immune response, both 
innate and adaptive, are key to controlling HIV-1 replication, which is counter-intuitive 
when compared with the protective humoral responses elicited by other viral 
vaccinations. HIV-specific CTL responses combined with over-expression of specific 
HLA-I alleles (HLA-B*57, HLA-B*27, and HLA-C) are associated with low viral loads 
(64, 65). Natural killer cells can become activated via HIV-1's downregulation of HLA-A 
and HLA-B proteins, leading to a stronger anti-HIV CD8+ T cell response via NK-DC 
cross-talk (66). Other cell types, including plasmacytoid dendritic cells, T regulatory 
cells, and Th17 cells are likely involved, but their specific roles are still unclear, 
especially how they could influence vaccination (67).  
One of the major obstacles to understanding exactly how an HIV-1 vaccine would 
function is the lack of a suitable animal model that can recapitulate a protective immune 

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response, or at least provide details of where a vaccine falls short. Such a model could 
save countless resources spent on large cohort vaccination studies and weaker animal 
models that fail to provide human correlative data. Currently macaques or chimpanzees 
are most commonly utilized, but non-human primates are unable to be infected with HIV-
1, leading researchers to depend on Simian Immunodeficiency Virus (SIV) or hybrid 
SHIV (HIV with an SIV envelope) infections in attempts to replicate human HIV-1 
infection. A mouse-model for HIV-1 infection could be a valuable resource for 
researchers seeking a model that more closely resembles the human immune system (59). 
 
1.12 Anti-retroviral Drugs 
The first anti-retroviral drug licensed for AIDS treatment in the United States was 
Zidovudine (AZT) (68). AZT is a nucleoside analog inhibitor of viral reverse 
transcriptase. This drug works by acting both as a competitor of normal nucleoside 
triphosphates and, when incorporated into viral DNA, acts as a chain terminator. AZT 
was successful initially but due to the rapid mutation rate of HIV long term treatment was 
not effective (69). The earliest protease inhibitors were made almost by chance as renin 
inhibitors, being developed as antihypertensive drugs, and were later adjusted for use in 
antiviral treatment. Derivatives and advances of these became the first generation of 
efficacious protease inhibitors (70). HIV-1 Protease is a virus encoded enzyme that is 
translated from a polycistronic RNA. Protease is required for infectivity of new virions 
and inhibition of this enzyme ablates viral infectivity. It was also quickly realized that 
efficiency of treatment could be increased, further delaying the onset of AIDS, when 

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three or more drugs were given as a combinatorial treatment. This treatment is known as 
Highly Active Antiretroviral Therapy (HAART) (71).   
Treatment of HIV/AIDS by HAART has been very successful, having substantial 
reduction in viral loads and in patients that had remarkable recoveries (70, 71). Patients 
that are successfully treated with HAART sustain viral load levels below detection limits. 
This suppression can remain for years and can prevent the onset of AIDS.  However, in 
all the years of HAART administration to HIV-1 infected patients none have been 
completely cleared of virus. This is clear when tissues are examined to show viral 
replication is not completely suppressed (72). Additionally, intermittent virus replication 
can occur allowing for the potential of drug-resistant viruses to emerge (72). Once these 
strains propagate, treatment efficacy becomes limited. Additionally, current HAART 
drugs must be taken regularly and even multiple times a day. These drugs also have 
significant side effects resulting in noncompliance of the patients. A major focus on drug 
development is timely dose efficacy and reduction or removal of side effects (72).  
Many steps in the HIV-1 replication cycle offer opportunities for possible 
intervention. One obvious candidate is the retroviral enzyme integrase. Structural data 
and biochemical information about this protein have become available, and potent 
inhibitors of its activity have been identified, such as the clinically approved anti-
retroviral drug raltegravir (73). Futher, inhibitors of HIV-1 fusion that target either viral 
envelope protein or host cell chemokine coreceptors have been proven efficacious (74). 




Even with all the advances in drug therapy many obstacles remain. For example 
to accomplish a cure via drug therapy, it will be necessary to develop drugs that can enter 
all virus accessible sites. This includes passing the blood brain barrier and targeting 
hematopoietic stem cells in the bone marrow (72). For drugs to be efficacious in long 
term treatment the viral reservoirs in latently infected quiesscent long-lived memory T 
cells must be addressed. Lastly, any treatment that is prolonged will develop 
autoimmunity untoward side effects, issues with anergy of the immune system, or 
activating it in an undesired way, and non-compliance from patients (73). Even with 
these difficulties the door to novel therapeutics for treatment and prevention of HIV-1 
infection and/or AIDS development remains wide open.   
 
1.13 Pre-exposure Prophylactics and Microbicides 
The first anti-HIV microbicides were developed in an attempt to disrupt viral 
infection, however, these drugs lacked specificity to HIV-1 and had limited neutralizing 
ability to multiple strains resulting in failed protection in field trials (75). The initial 
failure of microbicides was also due partly to the lack of a suitable animal model that 
used HIV-1 directly. Without this model only clinical trials that are expensive and rely 
heavily on patient compliance limit not only controlled testing but also wide range 
screening of potentially efficacious compounds. In this regard the SCID humanized 
mouse model was used for evaluating the efficacy of microbicides (76).  However, due to 
low levels of human cells in vaginal mucosa the vaginal infection rate was found to be 
variable making this model unreliable for microbicide testing (77). This limitation has 
thus been solved with the already discussed models (RAG-hu and BLT) which allow for 
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greater human cell engraftment resulting in higher levels of HIV-1 susceptible cells in the 
mucosa (57). Testing of potential HIV-1 microbicide compounds topically administered 
to vaginal or rectal mucosa has so far not been reported using these humanized mouse 
models (76). The majority of RT inhibitors such as tenofovir fill the list of potential anti-
HIV microbicide candidates (78, 79). Tenofovir has already been tested in human clinical 
trials and showed partial protection in the field, illustrating the potential for efficient and 
efficacious microbicides against HIV-1 (79).  
Another approach to preventative methods against HIV-1 is by systemically 
delivered pre-exposure chemo-prophylactic. A chemo-prophylactic can simply be the use 
of clinically approved effective compounds applied prior to HIV-1 exposure. An effective 
pre-exposure prophylactic (PrEP) that can prevent sexual transmission of HIV-1 is likely 
to play a major role in preventing millions of new cases (80). It will also empower 
women to protect themselves from HIV risk. The benefits of PrEP in the infectious 
disease field have been already well documented for the prevention of malaria and 
mother-to-child transmission in the case of HIV-1 (81-83). An effective PrEP, when 
available, is estimated to prevent 2.7 to 3.2 million new infections in sub-Saharan Africa 
and thousands of new cases in high risk individuals in the USA (84). 
Currently there are numerous clinically approved effective anti-retroviral drugs 
that are used to treat HIV infection and some of these can be potentially exploited for 
developing an effective PrEP (85, 86). That PrEP can prevent sexual transmission is 
substantiated by the early studies in non-human primates which employed daily oral 
administration of RT inhibitors tenofovir (TDF) and/or emtricitabine (FTC) (87-89). This 
concept has reached clinical trials in which tenofovir is currently being investigated for 

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its prophylactic efficacy (87). It is necessary to continually evaluate new candidates since 
a PrEP with proven protective efficacy now may not retain its effectiveness in the future 
years given the propensity of HIV-1 to develop drug resistance. While the monkey model 
has been very useful in evaluating appropriate candidate PrEPs, there are a number of 
limitations for its use to screen large numbers of potential candidates (89).  In this 
context, it was recently shown that tenofovir could prevent HIV-1 vaginal transmission 
using the BLT mouse model (90). Using the same model, it was also shown that systemic 
administration of TDF (tenofovir) and FTC (emtricitabine) prevents HIV-1 infection via 
vaginal and i/p challenges thus setting the stage for large scale evaluation of different 
anti-HIV compounds for their efficacy as PrEPs as well as topical microbicides in 
preventing HIV-1 infection (91). 
 
1.14 siRNA-based Therapeutics  
Small interfering RNAs (siRNAs) are 21-22 base long RNAs that guide sequence-
specific degradation of target mRNAs (92). The conserved biological response of the 
RNAi phenomenon was originally discovered in petunia flowers after a study to 
introduce a pigment producing gene under the control of a strong promoter gave an 
unexpected result of decreased pigment (93, 94). This silencing of the introduced gene 
along with the homologous endogenous gene was termed “cosuppression” (93, 94). 
Evidence that this gene silencing resulted from dsRNA was first reported after dsRNA 
was injected into Caenorhabditis elegans and complete silencing of the homologous gene 
was observed (95, 96). Later, this same phenomenon was verified in the Drosophila 
model after dsRNA was injected into embryos (97).  
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Given the ability to direct sequence specific silencing of target mRNAs, siRNAs 
have the potential to function as bio-drugs for treatment of a wide range of human 
maladies (98-101). Naturally occurring RNAi is initiated when the cell encounters long 
dsRNA molecules transcribed from viral infections, degenerate cellular transcripts, or 
endogenously transcribed micro RNAs (miRNAs). Once these dsRNA molecules are 
recognized cascades of events occur that involve the RNase-III like enzyme Dicer and the 
multi-protein complex, RISC (RNA induced silencing complex) (102-103).  Longer 
dsRNA molecules are cleaved by Dicer into 19-24bp dsRNA molecules which are then 
bound within the RISC complex (Figure 1.3). The RISC complex unwinds the short 
dsRNA and uses the antisense strand as a sequence specific guide. With this guide the 
RISC complex uses its endonuclease activity to degrade the homologous mRNA 
transcripts (Figure 1.3) (104, 105). In early studies using RNAi from long dsRNAs in 
mammalian cells resulted in the induction of interferon responses which shuts down 
cellular protein synthesis leading to cell death (106). This inhibited initial research with 
RNAi (107, 108). Later, small dsRNAs were utilized for sequence-specific inhibition of 
target mRNA without activating the interferon response (107).  To extend the half-life of 
intracellular siRNAs, certain modifications have been developed including protecting 
siRNAs from nucleases by 2’-OH modifications (108).  
Several recent studies have demonstrated the use of siRNAs in functionally down-
regulating expression of HIV-1 and host mRNAs against viral and cellular targets (100, 
109-111). In similarity with the use of HAART, siRNA-based therapeutics that target 
combinations of distinct genomic regions of HIV-1 or target HIV-1 host dependency 

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factors (HDFs) can be administered in a tailored fashion to minimize the possibility of 
viral escape mutants (113, 114).  
 
Figure 1.3 Mechanism of RNAi. Small interfering RNAs (siRNAs) are introduced to the cell exogenously 
or are expressed endogenously. These short dsRNA molecules are incorporated into the RISC complex where the 
antisense strand is used for sequence specific homologous mRNA target degradation.  
 
Although siRNAs hold promise for treatment of HIV/AIDS, efficient, systemic 
delivery of siRNA in vivo remains a principal challenge to achieve the desired RNAi 
potency for successful clinical application (115, 116). Most HIV-susceptible cells (such 
as, CD4+ lymphocytes and monocytes) are exceedingly difficult to transfect with non-
viral agents such as liposomes. Several delivery strategies such as carbon nanotubes 
(116) and carbosilane dendrimers (117) have been shown to deliver siRNAs into cultured 
human T cells and primary PBMCs. However, the complicated formulations (nanotube 
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functionalization and nanotube-siRNA conjugation) and high concentration of siRNA 
needed (> 300 nM in the case of carbosilane dendrimers) make them less favorable for in 
vivo anti-HIV applications. Other strategies, such as the use of cell-penetrating peptide-
dsRNA-binding fusion proteins (118), antibody Fab fragment-protamine fusions (119) 
and a CD7-antibody-polyarginine conjugate (120) have been used to functionally deliver 
siRNAs and induce RNAi responses in vivo without cytotoxicity. However, protein or 
antibody based delivery involves rather complex and expensive production processes, 
poor binding capacities for siRNAs and potential immunogenicity. Therefore, there is 
still a pressing need for developing simple and safe non-viral siRNA delivery systems for 
possible clinical applications.  
 
1.14a PAMAM Dendrimers 
Poly(amidoamine) (PAMAM) dendrimers are a class of highly branched, 
structurally well-defined chemical polymers which bear cationic primary amine groups 
on their spherical surface and are able to form stable and uniform nanoscale complexes 
with negatively charged nucleic acids via electrostatic interactions. Once formed, the 
complexes can protect nucleic acids from ribonuclease degradation and promote cell 
uptake via endocytosis (121, 122). The dendrimers possess numerous tertiary amines in 
the interior, which will be protonated in the acidic endosomes and thus lead to the 
osmotic endosome swelling (proton sponge effect) to promote the release of nucleic acids 
from dendrimer/nucleic acid complexes.  
A series of structurally flexible PAMAM dendrimers bearing a triethanolamine 
(TEA) core as effective vectors for RNA interaction (123) and siRNA delivery (124) 

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have been previously developed. The flexible structure imparts these dendrimers with 
stronger interactions with nucleic acids via a mutually induced fit process. At the same 
time, it promotes efficient dissociation of nucleic acids in endosomes via a proton sponge 
effect. Recently, these TEA-core PAMAM dendrimers have been used to deliver a heat 
shook protein (Hsp) siRNA into human prostate cancer (PC-3) cells, resulting in specific 
silencing of the Hsp gene and inhibition of cell proliferation (125). Thus, these 
dendrimers represent an attractive and relatively simple vehicle for siRNA delivery. 
 
1.14b gp120 Aptamer 
HIV-1 infection is initiated by the interactions between the external envelope 
glycoprotein gp120 of HIV and the human cell surface receptor CD4 (126-129), 
subsequently leading to fusion of the viral membrane with the target cell membrane (130, 
131). Thus, HIV-1 entry into its target cells represents an attractive target for new anti-
HIV-1 drug development (133-138). The most effective anti-HIV drugs used in the clinic 
consist of combinations of compounds that block the early reverse transcription step, and 
the late viral gag protein maturation step (139-141). Preventing the virus from binding to 
its primary receptor is one of the most obvious and direct ways to prevent infection. One 
rational antiviral approach is to create small ligands directed to the virus surface protein 
gp120. Successes in discovering new classes of gp120-directed inhibitors targeting initial 
step of HIV-1 entry have been reported in recent years (134, 141, 142). Soluble CD4 
(sCD4) has demonstrated efficacy against many laboratory strains (143, 144); however 
disappointing results from clinical trials were attributed to poor activity of this drug 
against primary isolates (145, 146). Another entry inhibitor PRO-542, a CD4-IgG 

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recombinant fusion protein effectively neutralizes many HIV-1 strains in cell culture 
(147, 148) as well as clinical isolates (149, 150), but unfortunately this drug has not 
enjoyed widespread use in clinical treatment of HIV-1 infection.  
Other inhibitors bind gp120 less specifically through electrostatic or lectin–
carbohydrate interactions [sulfated polymers, cyanovirin (151)]. These properties create 
challenges for the practical implementation of these molecules as drugs. In 2003, Martin 
et al. (152) designed a 27-aa CD4 peptide mimic, CD4M33, which was shown to bind to 
gp120 and inhibit HIV-1 infection in vitro. The clinical application of this peptide has not 
yet taken place though. Aside from antibody or peptide mimics, nucleic acid aptamers 
with low to mid-range nanomole binding affinities are an attractive class of therapeutic 
molecules (153–156). Aptamers which block the interaction of gp120 and CD4 have been 
previously developed. One such aptamer was shown to specifically interact with the 
conserved coreceptor interacting region of R5 strain gp120 (154). Although both 
aptamers and antibody or engineered peptide mimics have great specificity and binding 
affinity, the nucleic acid-based aptamers offer more synthetic accessibility, convenientce 
in modification, chemical versatility, stability and lack of immunogenicity (157). 
Therefore, aptamers can be utilized for flexible applications ranging from diagnostic to 
therapeutic assay formats (158,159). Aptamers that target specific cell surface proteins 
are employed as interesting delivery molecules to target a distinct cell type, hence 
reducing off-target effects or untoward side effects. The first example of aptamers used 
for siRNA delivery is an anti-PSMA aptamer (159) that binds tightly to the prostate-
specific membrane antigen (PSMA), a prostate cancer cell-surface receptor. 


McNamara et al. (160) in 2006 reported the use of this aptamer for receptor 
mediated siRNA delivery. In this study, they selectively delivered a 21-mer siRNA into 
PSMA expressing cells, resulting in silencing of target transcripts both in cell culture and 
in vivo following intra-tumoral delivery. Similarly, Chu et al. (161) used a modular 
streptavidin bridge to connect lamin A/C or GAPDH siRNAs to the biotinylated variants 
of this anti-PSMA aptamer. Consequently, this system induced silencing of the targeted 
genes only in cells expressing the PSMA receptor. The targeting properties of the anti-
PSMA aptamer also can be exploited for localizing other therapeutic agents to tumors 
such as a toxin (162), doxorubicin (163) or nanoparticles (164-167). We recently 
described a novel dual inhibitory function anti-gp120 aptamer-siRNA chimera, in which 
both the aptamer and the siRNA portions have potent anti-HIV activities as described in 
chapter five (168). Additionally, HIV gp120 expressed on the surface of HIV infected 
cells was used for aptamer-mediated delivery of an anti-HIV siRNA, resulting in 
pronounced inhibition of HIV replication in cell culture.  
For treatment of HIV using aptamer–siRNA chimeras, it is highly desirable to 
generate new aptamers to expand the diversity of target recognition for potential use in 
vivo. New anti-gp120 aptamers and various siRNAs targeting different genes could be 
combined to avert viral resistance to a single aptamer–siRNA combination. The aptamer 
approach thus provides a broad spectrum HIV-1 neutralizing agent and siRNA delivery 
vehicle.  The combined aptamer-siRNA approach is an attractive, non toxic therapeutic 




Among HIV-1 molecules the Tat and Rev proteins are essential for subsequent 
expression of HIV-1 structural genes (Gag, Pol and Env) and for the synthesis of full 
length viral genomic RNA (82). SiRNAs designed to destroy the tat/rev transcripts were 
found to be highly effective in viral suppression (116, 169, 170). With the advent of 
aptamer technology for targeted siRNA delivery it is now feasible to use the aptamer 
binding function for receptor mediated endocytosis of siRNAs (171-173).   
 
1.15 Gene therapy  
Without a complete cure available for complete removal of HIV-1, current 
therapeutics requires multiple treatments for continued viral suppression. Multiple 
treatments are expensive, require adherent behavior and may result in undesired side 
effects. In this regard anti-HIV gene therapy techniques hold considerable promise for 
efficacy from single treatment. Previous work has demonstrated this potential in vitro 
conveying viral resistance to primary T cells and macrophages (174-176). However, 
these cells do not continuously produce new cells and are subsequently eliminated from 
the body over time. To address this issue hematopoietic CD34+ stem cells (HSCs), 
originating in the fetal liver and later in the bone marrow, continuously produce the cells 
of hematopoietic origin that are the primary target cells of HIV. Promising data has been 
obtained showing that anti-rev siRNAs against HIV were functional in conferring viral 
resistance in differentiated T cells and macrophages derived from transduced CD34+ 
hematopoietic progenitor cells (177). The therapeutic transduction of anti-viral constructs 
should therefore focus on HSCs (178). An HIV resistant immune system harboring 
functional T cells, B cells and monocytes/macrophages transduced with anti-HIV 

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constructs can be developed and continuously replenished (178). This modified, HIV-
resistant immune system may detour AIDS progression, restore immune function as well 
as sufficiently lower HIV-1 viremia. This single treatment therapy could effectively 
replace HAART, conveying significant improvement to a patient's quality of life. 
The first retroviral vectors used in a gene therapy setting were derived from 
murine leukemia virus (178). However, these vectors preferentially integrated near 
transcriptional start sites (179). These vectors were also severely limited by their ability 
to only transduce dividing cells, due to their inability to transverse the nuclear membrane 
(180). This aspect of the murine leukemia vectors made the transduction of quiescent 
cells extremely difficult. The lentiviral vector system has proved advantageous for 
efficiently transducing specific genes into non-dividing cells (181). Although favorable, 
there are some concerns regarding safety using lentivirus vectors, including insertional 
mutagenesis and generation of recombinants. These concerns stem from lentiviral vectors 
tending to integrate in chromosomal regions that have a high concentration of transcribed 
genes (179). Although unlikely, it is possible that recombination of the lentiviral vectors 
and endogenous retroviral sequences could generate new viral strains.   
 To utilize the lentivirus as a safe vector numerous alterations were made including 
deleting the accessory proteins (Vif, Vpr, Vpu, and Nef) to decrease the likeliness of 
recombination and invoking an immune response, replacing the 5’ LTR U3 region with 
the cytomegalovirus immediate early promoter to allow the vector to be Tat independent 
and pseudotyping with a vesicular stomatitis virus envelope (VSV-G) gives a greater 
range of transducible cells (182-184). Additionally, a reporter gene, enhanced green 
fluorescent protein (EGFP), was included to detect transduction of target cells. Lentivial 

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vectors have been shown to be highly efficient in transducing hematopoietic stem cells 
(182). 
Using this vector system three anti-HIV constructs, each with its own method of 
action, were combined into a single Triple-R construct, providing a combinatorial 
approach to overcome escape mutations (185). The Triple-R construct is comprised of a 
tat/rev small interfering RNA, a CCR5 ribozyme and a TAR decoy, each of which has 
had its mode of action previously described, both in vitro and in vivo, for efficient 
intracellular immunization against HIV (185). Specifically, a tat/rev siRNA degrades the 
viral Tat and Rev transcripts affecting tat/rev regulatory junctions. The TAR decoy 
competes with Tat for binding to TAR, sequestering Tat protein function and decreasing 
transcription normally initiated by Tat (186). The CCR5 ribozyme binds to and cleaves 
CCR5 RNA transcripts, preventing the surface expression of CCR5, used as a co-receptor 
for infection by R5-tropic HIV-1 strains. We and others have shown that a strong down-
regulation of CCR5 is effective at blocking R5 strains, which are the most prevalent (187, 
188).  
This Triple-R construct has been previously evaluated in vitro showing long-term 
expression and anti-viral protection (175). We have also shown that Triple-R vector-
transduced HSCs undergo normal lineage specific differentiation in SCID-hu mice, 
giving rise to phenotypically normal transgenic T cells that are resistant to HIV infection 
(189). However, it is unclear if a more complete in vivo immune system can develop 
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Sexual HIV-1 transmission by vaginal route is the most predominant mode of 
viral transmission, resulting in millions of new infections every year. In the absence of an 
effective vaccine, there is an urgent need to develop other alternative methods of pre-
exposure prophylaxis (PrEP). Many novel drugs that are currently approved for clinical 
use also show great potential to prevent viral sexual transmission when administered 
systemically. A small animal model that permits rapid preclinical evaluation of potential 
candidates for their systemic PrEP efficacy will greatly enhance progress in this area of 
investigation. We have previously shown that RAG-hu humanized mouse model permits 
HIV-1 mucosal transmission via both vaginal and rectal routes and displays CD4 T cell 
loss typical to that seen in the human. Thus far systemic PrEP studies have been primarily 
limited to RT inhibitors exemplified by tenofovir and emtricitabine. In these proof-of-
concept studies we evaluated two new classes of clinically approved drugs with different 
modes of action namely, an integrase inhibitor raltegravir and a CCR5 inhibitor 
maraviroc as potential systemically administered chemo-prophylactics. Our results 
showed that oral administration of either of these drugs fully protects against vaginal 
HIV-1 challenge in the RAG-hu mouse model. Based on these results both these drugs 
show great promise for further development as orally administered PrEPs. 
 
2.2 Materials and Methods 
2.2a Generation of humanized Rag2-/-c-/- mice (RAG-hu mice) 
Humanized BALB/c-Rag2-/-c-/- (RAG-hu) mice were prepared by engraftment 
with human fetal liver-derived CD34+ hematopoietic progenitor cells as we previously 


described (55, 56).  Mice were maintained at the Colorado State University Painter 
Animal Center. These studies have been reviewed and specifically approved by the CSU 
Institutional Animal Care and Use Committee (Protocol 09-1460A). Briefly, newborn 
mice were conditioned by irradiating with 350 rads and then injected intrahepatically 
with 0.5-1x106 human CD34+ cells.  Mice were screened for human cell engraftment at 
10-12 weeks post-reconstitution.  Peripheral blood was collected by tail bleed and red 
blood cells were lysed by using the Whole Blood Erythrocyte Lysing Kit (R&D Systems, 
Minneapolis, MN).  The white blood cell fraction was stained with antibodies against the 
human pan-leukocyte marker CD45 (Caltag) and FACS analyzed to determine the levels 
of human cell engraftment as we previously described (55).  Individual peripheral blood 
engraftment levels in the mice vary, as previously described, hence female mice with 
varying human cell reconstitution levels greater than 40% (Table 2.1) were chosen for 
vaginal infections (55). 
 
2.2b Oral administration of anti-HIV drugs raltegravir and maraviroc and HIV-1 
challenge by vaginal route 
Female RAG-hu mice were administered with either raltegravir or maraviroc by oral 
gavage (6 mice each).  Clinical formulations of these drugs in tablet form Maraviroc 
(Selzentry) 150mg, Pfizer Labs; Raltegravir (Isentress) 400mg, Merck & Co were freshly 
dissolved in distilled water each day prior to oral gavage.  Mice received either 
raltegravir (3.28mg/mouse) or maraviroc (1.23mg/mouse) by oral gavage daily.  Mice 
were challenged with HIV-1 vaginally on the 4th day of treatment and the drug treatment 
continued for 3 more days.  For vaginal viral challenges, cell-free HIV-1 strain BaL-1  


Table 2.1 Summary of human cell engraftment levels in humanized (RAG-hu) mice* 
Uninfected Control  Non-Treated 
Mouse Gender %Engraftment Mouse Gender %Engraftment 
J667 Female 95.0 812 Female 91.6 
J666  Female 70.0 811 Female 69.3 
   810 Female 91.4 
   809 Female 83.9 
   J635 Female 45.4 
   J634 Female 83.2 
    J632 Female 75.0 
       
Raltegravir Treated  Maraviroc Treated  
Mouse Gender %Engraftment  Mouse Gender %Engraftment 
J683 Female 43.6  J672 Female 74.3 
J682 Female 47.0  J671 Female 65.8 
J681 Female 60.5  J670 Female 80.4 
J680 Female 62.6  J642 Female 81.1 
J637 Female 83.5  J641 Female 62.4 
J636 Female 70.0  J640 Female 67.2 
 
*Peripheral blood was collected from human CD34 cell reconstituted mice at 10-12 
weeks post engraftment.  White blood cell fraction was stained with human CD45 FITC 
conjugated antibody and analyzed by FACS to confirm human cell engraftment prior to 





(R5 tropic virus) contained in the original media used to produce the virus (RPMI 1640 
medium supplemented with 10% fetal bovine serum) was used.  Vaginal infections were 
performed in a volume of 25ul (200 TCID50 of BaL-1 virus). Sterile P200 tips that had 
been previously heated over a flame to smooth any abrasive surfaces were used to deliver 
the virus (56). Anesthetized mice were held in an inverted position for four minutes post-
inoculation to allow virus to adsorb and to prevent immediate discharge of virus.  Seven 
control non-treated mice were also challenged similarly by the vaginal route. Mice were 
monitored daily for any potential gross ailments due to the drugs and blood samples 
drawn weekly to assess plasma viremia. 
 
2.2c Measurement of viral loads 
To detect HIV-1 in plasma of infected mice by Q-RT-PCR, RNA was extracted 
from 25-50ul of EDTA-treated plasma using the QIAamp Viral RNA kit (Qiagen, 
Valencia, CA).  Q-PCR was performed using a primer set specific for the HIV-1 LTR 
sequence and a corresponding LTR specific probe as described previously (54,56).  To 
detect integrated virus, cellular DNA was extracted using QIAamp DNA Qiagen kit. The 
cellular DNA was subjected to Q-PCR to determine the proviral loads.  
 
2.2d Flow cytometry 
Whole blood was collected and red blood cells lysed as reported previously (55, 
56).  Peripheral blood cells were stained for hCD3-PE and hCD4-PECy5 (Caltag) 
markers and analyzed using a Coulter EPICS XL-MCL FACS analyzer (Beckman 
Coulter, Fullerton, CA).  CD4+ T cell levels were calculated as a ratio of the entire CD3 

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population (CD4+CD3+:CD4-CD3+).  To establish baseline CD4+ T cell ratios, all mice 
were analyzed prior to infection.   
 
2.3 Results 
2.3a Oral administration of integrase inhibitor raltegravir protects humanized mice 
from HIV-1 infection via vaginal challenge 
We have previously shown that RAG-hu mice are susceptible to HIV-1 infection 
via both vaginal and rectal routes (55). Here we used this model to determine if systemic 
administration of raltegravir protects against vaginal HIV-1 challenge. Mice were 
administered with the drug daily by oral gavage since this drug is taken orally in a 
clinical setting. Vaginal viral challenge was performed on the 4th day and the drug 
treatment continued for three more days. To determine the status of HIV infection, mouse 
plasma and cellular blood fractions were analyzed by Q-PCR on a weekly basis. Our 
results showed that all of the non-treated infected mice became virus positive by the 5th 
Figure 2.1 Oral administration of raltegravir or maraviroc protects humanized mice against vaginal HIV-1 
challenge.  RAG-hu mice were challenged by vaginal route after oral administration of raltegravir or maraviroc as 
described in Methods. Blood was collected weekly from infected mice and the status of HIV-1 infection was 
determined by Q-RT-PCR. The viral challenge experiments were performed at same time for both of the drugs and the 
same set of control non-treated infected mice were used for comparison. Kaplan-Meier plots of time course of 





week post challenge (Fig 2.1A). Persistent viremia in plasma and proviral loads in the 
cellular fractions was observed throughout the evaluation period with viral loads reaching 
106 copies/ml (Fig 2.2).  
Figure 2.2 RNA and DNA viral loads in mice administered with raltegravir.  RAG-hu mice were challenged by 
vaginal route after oral administration of raltegravir as described in Methods. Blood was collected weekly. Viral RNA 
was extracted from the plasma fraction and DNA was extracted from the cellular fraction. Viral RNA and DNA loads 
were determined by Q-RT-PCR as described in methods. A. RNA viral loads B. DNA viral loads.   
 
 
In contrast, none of the raltegravir treated mice became infected at 5 weeks post-viral 
challenge unlike the non-treated mice (Fig 2.1A). Since it is possible that the drug 
treatment might have delayed the onset of infection, mice were followed for an additional 
5 weeks.  No evidence of infection was seen throughout the 10 week observation period 
as evaluated by either RNA or DNA PCR (Fig 2.2). These data collectively suggest that 
oral administration of raltegravir fully protects mice against HIV-1 viral challenge.  
 
2.3b Oral administration of CCR5 inhibitor maraviroc protects humanized mice 
from HIV-1 infection via vaginal challenge 
In addition to the viral integrase inhibitor raltegravir, we also evaluated a CCR5 
antagonist maraviroc to determine its efficacy in preventing HIV-1 infection via vaginal 
challenge using a similar protocol, like above. This experiment was done at the same time 


and the same non-treated virus infected animals were used as controls.  Maraviroc was 
also administered orally like above in a similar time scale. Our results showed that while 
all the seven control untreated mice became virus positive by the fifth week, none of the 
six maraviroc treated mice became infected throughout the ten week observation period 
(Fig 2.1B). Both RNA PCR to detect plasma viremia and DNA PCR to detect integrated 
provirus in blood cellular fractions were negative in maraviroc treated mice in contrast to 
non-treated virus challenged mice (Fig 2.3). These results showed that oral administration 
of maraviroc fully protects humanized mice against vaginal infection.  
Figure 2.3 RNA and DNA viral loads in mice administered with maraviroc.  RAG-hu mice were challenged by 
vaginal route after oral administration of raltegravir as described in Methods. Blood was collected weekly.Viral RNA 
was extracted from the plasma fraction and DNA was extracted from the cellular fraction.Viral RNA and DNA loads 
were determined by Q-RT-PCR as described in methods. A.  RNA viral loads B. DNA viral loads.   
 
2.3c CD4 T cell loss in non-drug treated mice versus raltegravir and maraviroc 
treated mice following vaginal infection.   
The above criteria of viral detection showed that both raltegravir and maraviroc 
treated mice were fully protected from vaginal HIV-1 challenge. Since CD4 T cell loss is 
a main characteristic of HIV-1 infection in humanized mice akin to that seen in the 
human, we further evaluated the virus challenged mice for any evidence of such loss (55, 
56). Accordingly, peripheral blood was collected weekly and subjected to FACS analysis. 

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Baseline CD4 T cell levels for each of the experimental mice was determined prior to 
viral challenge and these values were compared to the levels post-viral challenge. While 
there was a clear pattern of CD4 T cell decline in un-treated mice, their levels were stable 
in both groups of mice receiving raltegravir or maraviroc further confirming the absence 
of HIV-1 infection in these mice (Fig 2.4). 
Figure 2.4 CD4 T cell decline in non-treated vaginally challenged mice in contrast to mice protected with 
raltegravir and maraviroc treatment. Levels of CD4 T cells were monitored on a weekly by FACS basis to 
determine their decline in treated versus non-treated mice. Baseline values for each of the mice were established prior 
to infection as described in Methods. A. Raltegravir treated, B. Maraviroc treated 
 
2.4 Discussion 
Here we have shown that oral administration of two clinically approved drugs 
namely, raltegravir or maraviroc fully protect humanized mice against HIV-1 infection 
from vaginal viral challenge suggesting their potential utility as PrEPs. These two 
compounds have different modes of action (190). Maraviroc is a low molecular weight 
CCR5 antagonist which inhibits the binding of the natural ligands of CCR5, namely 
chemokine ligand 3 (CCL3 also known as MIP-1a), CCL4 (MIP1-b) and CCL5 
(RANTES) (191). It is a functional CCR5 antagonist devoid of agonist activity and 
shown to have a long lasting physical and functional occupancy of CCR5 leading to 

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sustained antiviral activity (192). It has been shown to have potent effect against all R5 
tropic viruses representing various viral clades in addition to being effective against a 
wide range of drug resistant viruses (193). Topical vaginal application of maraviroc as a 
microbicide was recently shown to protect rhesus monkeys against SHIV virus challenge 
(194). Raltegravir is an integrase strand transfer inhibitor that interferes with the viral 
DNA integration which is an essential step in viral replication. It is active against 
multidrug-resistant and both CCR5-tropic and CXCR4-tropic HIV-1 strains (195, 196). 
To our knowledge this is the first report evaluating these two drugs as potential systemic 
PrEPs against HIV-1 vaginal transmission. 
To simulate the clinical situation in mice, we administered each of the drugs 
orally as the prescription suggested for human use thus permitting intestinal absorption 
and reaching systemic effective concentrations. With regards to oral dosing in these 
proof-of-concept studies, we treated the animals for three days with the drug to achieve 
systemic drug equilibrium in vivo prior to vaginal challenge and continued the drug 
treatment for an additional four days. In these treated animals we preferred mice with 
higher engraftment in the chance that this aspect would result in a higher probability of 
infection.  This is similar to the studies of Denton et al in BLT mice that employed 
FTC/TDF (Truvada) for PrEP testing (91). Whereas the drug combination FTC/TDF 
(Truvada) was injected i/p to the mice to demonstrate PrEP efficacy in the above studies, 
we used oral administration as clinically suggested for the above drugs. While all the 
control non-treated, vaginally HIV-1 challenged mice became infected within five weeks, 
none of the raltegravir or maraviroc treated mice (6 mice each) showed any evidence of 
infection. Furthermore, DNA extracted from splenic tissue samples after euthanizing the 

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mice at sixteen weeks post-challenge also did not show any evidence of infection by PCR 
analysis (data not shown).  Thus protection conferred by either of these two drugs is 
highly significant (p value 0.0006, Fisher's exact test). We further evaluated the mice for 
evidence of helper CD4 T cell loss which is a characteristic hallmark of HIV-1 infection. 
As expected, a declining trend for CD4 T cell counts was observed in control non-treated 
mice in contrast to either of the treatment groups receiving raltegravir or maraviroc (Fig 
2.4).  These data collectively showed that treated mice resisted vaginal viral challenge 
thus indicating full protection in contrast to non-treated mice. To further, no animals were 
seen to have gross adverse side effects when monitored daily.    
Whereas topical microbicides received the major attention other than vaccines to 
preventing HIV infection thus far with many clinical trials currently ongoing in the field, 
experimental studies on systemic PrEPs for HIV have been limited to very few 
compounds with a main focus on RT inhibitors (80, 197, 198). These included tenofovir, 
emtricitabine and efavirenz which showed efficacy in non-human primates against i/v, 
vaginal or rectal challenges with either SIV and/or different versions of SIV/HIV 
chimeric viruses (90, 197). In addition to showing efficacy in the monkey models, the RT 
inhibitors tenofovir and emtricitabine also showed efficacy in the BLT mouse model 
against HIV challenge (91). Based on the effectiveness of tenofovir as a PrEP in the 
experimental studies it is currently in clinical trials to evaluate its efficacy in the human 
(199). With regard to fusion inhibitors, oral administration of CMPD167, a small 
molecule CCR5 inhibitor, protected macaques against vaginal SHIV viral challenge 




Our present results have provided the proof-of-concept data for further 
investigating  the potential of raltegravir and maraviroc as PrEPs thus identifying 
additional novel class of molecules with different modes of action (80, 191). Based on 
their proven broad spectrum of activity against divergent HIV strains in the clinic, both 
these drugs make excellent candidates for PrEP. In this proof-of-concept study only one 
dose given sequentially for 7 days was tested and found to be efficacious in the 
prevention of HIV-1 infection. Future studies should evaluate variations in the dose, 
timings of drug administration prior to vaginal challenge and duration of efficacy without 
further dosing after viral challenge to determine the memory effect. Additionally, 
although not tested in these studies, drugs with a similar mechanism may be examined in 
the future for their likely similar protection.  It is also necessary that field and drug 
resistant viruses be tested in this humanized mouse model. Furthermore, use of more than 
one drug in any PrEP will be more effective in field conditions. This can also be tested in 
this mouse model using a combination of raltegravir and maraviroc to derive pre-clinical 
data. Such evaluations will fine tune the PrEP regimens to be more practically applicable 
for clinical testing.  
In addition to the systemic PrEP, another highly promising method of prevention 
of HIV-1 sexual transmission is the topical use of effective microbicides as mentioned 
above. Therefore, testing of raltegravir and maraviroc as topical microbicides in the 
RAG-hu mouse model of sexual HIV-1 transmission is likely to provide critical pre-
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For prevention of HIV infection many currently licensed anti-HIV drugs and new 
ones in the pipeline show potential as topically applied microbicides. While macaque 
models have been the gold standard for in vivo microbicide testing, they are expensive 
and sufficient numbers are not available. Therefore, a small animal model that facilitates 
rapid evaluation of potential candidates for their preliminary efficacy is urgently needed 
in the microbicide field. We previously demonstrated that RAG-hu humanized mouse 
model permits HIV-1 mucosal transmission via both vaginal and rectal routes and that 
oral pre-exposure chemo-prophylactic strategy could be tested in this system. Here in 
these proof-of-concept studies, we extended this system for topical microbicide testing 
using HIV-1 as the challenge virus. Maraviroc, a clinically approved CCR5 inhibitor drug 
for HIV treatment, was formulated as a microbicide gel at 5 mM concentration in 2.2% 
hydroxyl ethyl cellulose. Female RAG-hu mice were challenged vaginally with HIV-1 an 
hour after intravaginal application of the maraviroc gel. Our results showed that 
maraviroc gel treated mice were fully protected against vaginal HIV-1 challenge in 
contrast to placebo gel treated mice which all became infected. These findings highlight 
the utility of the humanized mouse models for microbicide testing and, together with the 
recent data from macaque studies, suggest that maraviroc is a promising candidate for 







3.2 Materials and Methods 
3.2a Preparation of humanized Rag2-/-c-/- mice (RAG-hu mice) 
Humanized BALB/c-Rag2-/-c-/- (RAG-hu) mice were generated by transplanting 
with human fetal liver-derived CD34+ hematopoietic progenitor cells as we previously 
described (55, 56).  Briefly, newborn mice were conditioned by irradiating at 350 rads 
and then injected intrahepatically with 0.5-1x106 human CD34+ cells.  Mice were 
screened for human cell engraftment at 10-12 weeks post-reconstitution.  Peripheral 
blood was collected by tail bleed and red blood cells were lysed by using the Whole 
Blood Erythrocyte Lysing Kit (R&D Systems, Minneapolis, MN).  The white blood cell 
fraction was stained with antibodies against the human pan-leukocyte marker CD45 
(Caltag) and FACS analyzed to determine the levels of human cell engraftment as we 
previously described (56). Female mice with over 60% engraftment were chosen for 
vaginal infections as detailed below.  
 
3.2b Vaginal application of gel and HIV-1 challenge by vaginal route  
Female RAG-hu mice were topically administered with either a placebo gel or an 
anti-retroviral gel formulation an hour before viral challenge. Clinical formulations were 
ground and freshly dissolved in phosphate-buffered saline, sterile-filtered and adjusted to 
a final known concentration.  A 3.4% gel preparation of hydroxyl-ethyl cellulose (HEC) 
was added to the dissolved drug to achieve a final concentration of 0.4mM, 1mM, or 
5mM in 2.2% HEC gel. A 25µl volume of the gel formulation was carefully applied in to 


the vaginal vault of mice. Control mice received 2.2% HEC placebo gel. An hour post-
gel application, mice were challenged vaginally with HIV-1 BaL (3000 TCID) in a 25µl 
volume. The gel and viral inoculums were applied by using the bulbous end of a gavage 
needle to assure no abrasions and tearing. Anesthetized mice were held in an inverted 
position for four minutes post-inoculation to allow virus to adsorb and to prevent 
immediate discharge of virus as described previously (56, 201). Animals were observed 
daily and blood samples collected on a weekly basis to assess plasma viremia and CD4 T 
cell counts. 
 
3.2c Measurement of viral loads 
Viral infection and viral loads were assessed by Q-RT-PCR. RNA was extracted 
from 25-50ul of EDTA-treated plasma using the QIAamp Viral RNA kit (Qiagen, 
Valencia, CA).  Q-PCR was performed by using a primer set specific for the HIV-1 LTR 
sequence and a corresponding LTR specific probe as described previously (201).  To 
detect integrated form of the virus, cellular DNA was extracted from the cellular fraction 
using the QIAamp DNA Blood kit (Qiagen, Valencia, CA) and subjected to Q-RT-PCR 
by the iQ SYBR Green Supermix (Bio-Rad, Hercules, CA) to determine proviral loads. 
 
3.2d Flow cytometry 
Mice were monitored to measure the levels of CD4 T cells in the peripheral 
blood. Whole blood was collected and red blood cells lysed as reported previously (55, 
56).  Peripheral blood cells were stained for hCD3-PE and hCD4-PECy5 (Caltag) 


markers and analyzed using a Coulter EPICS XL-MCL FACS analyzer (Beckman 
Coulter, Fullerton, CA).  CD4+ T cell levels were calculated as a ratio of the entire CD3 
population (CD4+CD3+:CD4-CD3+). All mice were analyzed prior to infection to 
establish baseline CD4+ T cell ratios. 
 
3.3 Results 
3.3a Vaginal application of anti-retroviral gels partially protect humanized mice 
against HIV-1 vaginal challenge 
In our preliminary studies we evaluated topically applied microbicide gels to prevent 
HIV-1 sexual transmission. To assess efficacy, the various compounds were administered 
vaginally one hour prior to vaginal viral challenge to mimic a coital dependant context, 
including gels formulated with tenofovir, raltegravir, maraviroc and a cocktail of the 
three drugs.  Mouse plasma and blood cellular fractions were analyzed by Q-PCR weekly 
to ascertain HIV-1 infection status. These results showed limited protection at a 0.4mM 
active drug concentration (Fig3.1A).  With these studies the previously evaluated  
Figure 3.1 Vaginal application of .4mmol and 1mmol anti-retoviral gel formulations partially protect humanized 
mice against vaginal HIV-1 challenge.  RAG-hu mice were challenged by vaginal route one hour after vaginal 
administration of treatment as described in Methods at a concentration of A) .4mmol and B) 1mmol. Blood was 
collected weekly from infected mice and the status of HIV-1 infection was determined by Q-RT-PCR. Kaplan-Meier 
plots of time course of appearance of viremia in drug treated versus non-treated virus challenged mice.  


tenofovir was used as a effective control.  In this regard when the microbicide gel was 
formulated with 0.4mM active drug tenofovir had the best protection but was only able to 
protect 25% of the mice (Fig3.1A).  
To derive better protection the active drug concentration was increased to 1mM.  
The 1mM provided slightly higher partial protection as seen in three antiretroviral drug 
treated groups (Fig 3.1B). These data, although only deriving partial protection, are 
promising in proof of principal further supported by the delayed infection rates seen in all 
treated groups (Fig 3.1B).  
 
3.3b Vaginal application of maraviroc gel protects humanized mice against HIV-1 
vaginal challenge 
Upon further optimization for a topical applied microbicide, including utilizing a 
bulbous gavage needle for non abrasive application, maraviroc was chosen as it is an 
extra-cellular effective molecule (Fig 3.1A and B). To assess efficacy, maraviroc was 
administered one hour prior to vaginal viral challenge to mimic a coital dependant 
context. Mouse plasma and blood cellular fractions were analyzed by Q-PCR weekly to 
ascertain HIV-1 infection status.  Our results showed that the placebo-gel administered 
and HIV-1 challenged mice started becoming virus positive by the third week with all of 
them infected by the 5th week post challenge (Fig 3.2). Persistent viremia in plasma and 
proviral loads in the cellular fractions were observed throughout the evaluation period 
with viral loads reaching up to 106 RNA copies/ml (Fig 3.3A) and proviral DNA copies 


at 105 DNA copies/ml (Fig. 3.3B).  In contrast, none of the maraviroc treated mice 
became infected (Fig 3.3A). No evidence of infection was seen throughout the 16 week 
observation period as evaluated by either RNA or DNA PCR (Fig 3.3A and B). These 
data taken together suggest that vaginal administration of maraviroc fully protects mice 
against HIV-1 viral challenge.  
 
Figure 3.2 Vaginal application of maraviroc 
gel protects humanized mice against vaginal 
HIV-1 challenge.  RAG-hu mice were 
challenged by vaginal route one hour after 
vaginal administration of maraviroc as 
described in Methods. Blood was collected 
weekly from infected mice and the status of 
HIV-1 infection was determined by Q-RT-PCR. 
Kaplan-Meier plots of time course of 
appearance of viremia in drug treated versus 




Figure 3.3 RNA and DNA viral loads in mice administered with maraviroc.  RAG-hu mice were challenged by 
vaginal route after an hour after vaginal application of maraviroc as described in Methods. Blood was collected weekly. 
Viral RNA was extracted from the plasma fraction and DNA was extracted from the cellular fraction.   Viral RNA and 






3.3c CD4 T cell loss following HIV-1 vaginal infection in placebo-gel administered 
mice compared to maraviroc-gel administered mice 
A typical finding in HIV-1 infected humanized mice is a gradual CD4 T cell loss 
as seen in the human. Although the PCR data demonstrated no viral infection in 
maraviroc treated mice, we further evaluated the virus challenged mice for any evidence 
of CD4 T cell loss to confirm lack of any HIV associated pathology (55, 56). Peripheral 
blood was collected bi-weekly and subjected to FACS analysis. To establish a baseline, 
CD4 T cell levels were measured prior to viral challenge for each of the experimental 
mice and later compared to the levels determined post-viral challenge. While there was a 
clear pattern of CD4 T cell decline in placebo-gel treated and viral challenged mice, their 
levels were stable in mice receiving maraviroc gel (Fig. 3.4) further validating the 
prevention of HIV-1 transmission in these mice. 
Figure 3.4.  CD4 T cell decline in non-treated vaginally challenged mice in contrast to mice protected with 
maraviroc gel. Levels of CD4 T cells were monitored on a weekly basis by FACS basis to determine their decline in 






With dearth of a protective vaccine in the immediate future, deployment of an 
effective vaginally applied anti-HIV microbicide would greatly aid in stemming the HIV 
epidemic (202). To reach this goal, new viral specific anti-HIV compounds need to be 
tested as microbicides using a suitable in vivo system.  
In these proof-of-concept studies, we have shown that topical microbicide gel 
formulations partially protect humanized mice from HIV-1 challenge via vaginal route 
which is the predominant mode of viral transmission. While these studies initially did not 
fully protect against HIV vaginal infection their findings aided in optimization of gel 
formulations and topical application. With these developments we successfully 
formulated a complete protection against HIV vaginal transmission using the CCR-5 
antagonist maraviroc.   
While a recent study had shown the efficacy of maraviroc in preventing vaginal 
infection in rhesus macaques by a hybrid virus, namely CCR-5 using SHIV-162P3 (203), 
our results demonstrated the efficacy of the drug against HIV-1 in a human target cell 
context in humanized mice. In addition to supporting the results of the macaque studies, 
our findings extended them to the primary culprit HIV-1 itself against which the drug is 
originally designed and intended thus providing more direct evidence.  
Due to its capacity as a CCR5 antagonist, the small molecular drug maraviroc 
inhibits the binding of native physiological ligands of CCR5, namely CCL3 (also known 
as MIP-1a), CCL4 (MIP1-b) and CCL5 (RANTES) (192). It is shown to have sustained 
antiviral activity due its long lasting physical and functional occupancy of CCR5 
receptor. It has potent effect against all R5 tropic viruses representing various viral 


clades, and is also shown to be effective against a wide array of drug resistant viruses 
(193). A major advantage with drugs such as maraviroc compared to RT inhibitors is that 
the first step in infection, viral entry, is inhibited thus providing an up-front protection. 
To simulate the use of the microbicide in coital context, gel formulations were 
applied vaginally one hour before HIV-1 R5 viral challenge. In contrast to the macaque 
studies, it was not necessary to subject the humanized mice to Depo-Provera 
(progesterone) hormonal treatment to induce vaginal thinning for achieving efficient 
vaginal infection. The 5mM maraviroc concentration we used is close to the dose (6mM) 
found to be most protective in monkey studies using a similar 2.2% HEC carrier gel 
formulation (194). While all the placebo-gel treated, vaginally HIV-1 challenged mice 
(n=6) became infected within five weeks, none of the maraviroc treated mice (n=7) 
showed any evidence of infection by either RT-PCR or DNA-PCR throughout the sixteen 
week observation period.  Thus protection conferred by maraviroc gel against HIV-1 
vaginal challenge is highly significant (p value 0.0006, Fisher's exact test). In addition to 
viral detection, we also looked for any evidence of helper CD4 T cell loss which is a 
typical feature of HIV-1 infection. A trend of declining CD4 T cell counts was noticed as 
expected in placebo-gel treated mice in contrast to those receiving maraviroc (Fig 3.4). 
These data taken together showed that maraviroc fully protected mice from vaginal HIV-
1 challenge. 
The above promising data together with those using SHIV viral challenges in 
macaques strongly suggest maraviroc as an attractive candidate for further development 
as a topically administered anti-HIV microbicide. Since it is not yet widely used in other 
parts of the world where HIV prevalence is high, it will have a good resistance barrier. 


However it should be noted that maraviroc will not protect against X4 tropic and/or dual 
tropic viruses. With regard to the drugs that are in clinical trials or nearing that stage, the 
HIV microbicides arena is currently focused on only a few HIV-1 specific compounds 
such as RT inhibitors tenofovir and emtricitabine (197). While the partial protection 
afforded by tenofovir gel is encouraging, it is by no means adequate to be deployed as a 
sole candidate to protect the large at-risk population (199). Therefore, it is necessary that 
many new compounds be tested to identify candidates with a good chance for success. 
Furthermore, it is generally understood that a single drug would not be adequate to 
achieve broad efficacy and therefore a combination of drugs need to be tested.  Such 
testing in a primate model will be cost-prohibitive (203, 204). In this regard, humanized 
mice are likely to fill the gap for deriving preliminary data and in laying the ground work 
for subsequent macaque studies. Since HIV-1 itself can be used as a challenge virus, 
various drug resistant mutants that exist in the field can also be evaluated against 
different combinations of potential promising compounds. 
While both RAG-hu mice and BLT mice models have been successfully used to 
demonstrate the efficacy of systemically administered anti-HIV drugs for pre-exposure 
prophylaxis (65, 205), our present results have extended the utility of RAG-hu mouse 
model for micobicide testing as well. In the future, both these models are likely to play an 
important role in the development of new PrEP strategies that encompass systemic and 
topical use of anti-HIV drugs (206).  In this context, the RAG-hu mouse model offers 
some practical advantages over BLT mice. First, its preparation is not technically 
intensive as no surgical procedure is required to implant thymic and liver tissues under 
the kidney capsule as is necessary to generate BLT mice.  Second, RAG-hu mice have a 


longer life span compared to BLT mice (NOD/SCID mice used to prepare BLT mice 
experience a high incidence of lymphomas), thus permitting long-term studies.  For 
example, effect of microbicides on the mucosal membranes during long-term application 
can be evaluated.  Third, for any large scale testing, an adequate cohort of humanized 
mice is needed.  In this regard, greater numbers of RAG-hu mice can be generated per 
human tissue donor compared to BLT mice. 
In summary, we have shown that various clinically approved compounds derive 
some protection and that the CCR5 inhibitor maraviroc formulated as a topical gel can 
completely prevent HIV-1 vaginal transmission. These data also helped validate the 
utility of humanized mice for testing topical microbicides. Now it is possible to conduct 
large scale in vivo preliminary screenings of a large number of potential microbicide 
candidates in a cost effective manner.   
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The potent ability of small interfering (si)RNAs to direct inhibition of the 
expression of complementary RNA transcripts is being exploited as a possible therapeutic 
approach for the treatment of a variety of diseases. Although current anti-retroviral drug 
therapies for treatment of HIV/AIDS show considerable promise, there are still associated 
problems of toxicity, viral resistance and cost for a daily, lifelong medication. In this 
regard, systemic administration of siRNAs targeting host and viral transcripts is an 
attractive alternative, but delivery of the siRNAs remains a key obstacle to successful 
therapeutic applications and clinical development. 
To address this problem we evaluated the in vivo efficacy of structurally flexible, 
cationic PAMAM dendrimers (Figure 4.1) as a siRNA delivery system in a Rag2-/-c-/- 
(RAG-hu) humanized mouse model for HIV-1 infection. HIV-infected humanized Rag2-/-
c-/- mice (RAG-hu) were injected intravenously with dendrimer-siRNA complexes 
consisting of a cocktail of siRNAs targeting both viral and cellular transcripts. We report 
in this study that the dendrimer-siRNA treatment suppressed HIV-1 infection by several 
orders of magnitude and protected against viral induced CD4 T-cell depletion. We also 
demonstrate that follow up injections of the dendrimer-siRNAs following viral rebound 
resulted in complete inhibition of HIV-1 titers. Collectively, these data demonstrate that 
dendrimer-mediated delivery system has the capacity for combining anti-viral and anti-
host siRNAs to avert viral escape mutants and suppress viral loads in vivo. The dendrimer 
delivery approach therefore represents a promising method for systemic, delivery of 
combinations of siRNAs for treatment of HIV-1 infection. 

Figure 4.1: Structure of a flexible poly(amidoamine) (PAMAM) dendimer with a 
the terminal amino groups (NH2) possess positive charges 
is shown as an example. 
 
4.2 Materials and Methods
4.2a Materials  
Unless otherwise noted, all 
restriction enzymes were obtained from New England BioLabs (NEB) and all cell culture 
products were purchased from GIBOC (Gibco BRL/Life Technologies, a division of 
Invitrogen.). Reverse transcriptase III, R
(Invitrogen, CA); Lipofectamine 2000 (Invitrogen, CA); Trans IT
WI); (Invitrogen); DNase I (Ambion); HEK 293 and CCRF

triethanolamine core. At pH 
via protonation. For clarity, the generation 3 (
 
chemicals were purchased from Sigma
andom primers and oligo(dT)










NL4.3 and HIV-1 IIIB viruses were obtained from the AIDS Research and Reference 
Reagent Program. 
siRNAs: siRNA and Cy3-labeled single strand RNA were purchased from Integrated 
DNA Technologies (IDT).  
Site I (tat/rev) 27 mer: Sense: 5’- GCG GAG ACA GCG ACG AAG AGC UCA UCA -
3’; Antisense: 5’- UGA UGA GCU CUU CGU CGC UGU CUC CGC dTdT-3’;  
Mutated Site I (tat/rev) 27 mer: Sense: 5’-GCG CUA ACA GCG UGU AAG AGC GAC 
UCA -3’; Antisense: 5’- UGA GUC GCU CUU ACA CGC UGU UAG CGC UU -3’. 
(The mutated sequences were underlined.) 
Anti-CD4 21 mer: Sense:  5’ - GAU CAA GAG ACU CCU CAG U dGdA - 3’; 
Antisense: 5’- ACU GAG GAG UCU CUU GAU C dTdG -3’ 
Anti-CD4 27 mer: Sense:  5’- GAU CAA GAG ACU CCU CAG UGA GAA G -3’; 
Antisense: 5’- CUU CUC ACU GAG GAG UCU CUU GAU CUG -3’ (2’-OMe 
modified U was underlined.) 
Anti-TNPO3 21 mer: Sense: 5’ - CGA CAU UGC AGC UCG UGU AUU -3’; Antisense: 
5’- UAC ACG AGC UGC AAU GUC GUU -3’. 
Anti-TNPO3 27 mer: Sense: 5’- CGA CAU UGC AGC UCG UGU ACC AG dGdC -3’; 





4.2b Dendrimer synthesis and characterization  
The PAMAM dendrimers were synthesized as previously described and 
characterized by IR, NMR, MS and HPLC (121, 122) 
 
In vitro assay: 
4.2c Agarose gel analysis of siRNA-dendrimer complexes  
The dendrimers were serially diluted to an appropriate concentration in 50 mM 
Tris-HCl buffer (pH 7.4), with all solutions stored at -20°C. The 27 mer Tat/rev siRNA 
was diluted with H2O. Both solutions were mixed at various N/P (= [total end amines in 
cationic dendrimer] / [phosphates in siRNA]) ratios and incubated at 37°C for 30 min in 
Tris-HCl buffer. The final concentration of siRNA was adjusted to 25 ng/µL (100 ng per 
well). After incubation the binding complexes were loaded on a 1.2% agarose gel for 
electrophoresis. The siRNA bands were stained by ethidium bromide and then detected 
by a Herolab EASY CCD camera (Type 429K) (Herolab, Wiesloch, Germany). 
 
4.2d Stability of siRNA-dendrimer complexes against RNase A 
An aliquot of 27 mer Tat/rev siRNA (1 µg) and the indicated amounts of 
dendrimers were kept at 37°C for 30 min. The complexes were then incubated in the 
presence of 0.01 µg/µL RNase A for different times as indicated in the gel at 37°C. 
Aliquots (4 µL) of the corresponding solution were withdrawn, added to 1.5 µL 1% SDS 

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solution on ice, and the subjected to electrophoresis in 1.2% agarose gel in standard TBE 
buffer. The siRNA bands were stained by ethidium bromide and then detected by a 
Herolab EASY CCD camera (Type 429K) (Herolab, Wiesloch, Germany). 
 
4.2e Transmission electron microscopy (TEM) analysis  
Studied were performed with a JEM-2000FX transmission electron microscopy. 
A solution (10 µL) of 27 mer Tat/rev siRNA (5 ng/µL) was mixed with a solution (10 
µL) of G5 dendrimer in Opti-MEM transfection medium. After equilibration (30 min), 
this mixture (4 µL) was dropped on a standard carbon-coated copper TEM grid and 
allowed to evaporate (1 h at 30°C, ambient pressure). In the case of siRNA-dendrimer 
solutions, the samples were premixed and allowed to equilibrate for 30 min before 
placing on the grid. The grid was then stained with uranyl acetate (2% in 50% alcoholic 
solution) for 3 min. Imaging was performed after air-drying for 20 min. 
 
4.2f Cell culture  
HEK 293 cells and CCRF-CEM cells were purchased from ATCC and cultured in 
DMEM and RPMI 1640 supplemented with 10% FBS. CHO-WT and CHO-EE cells 
were obtained through the AIDS Research and Reference Reagent Program and were 




PBMCs. Peripheral blood mononuclear samples were obtained from healthy 
donors from the City of Hope National Medical Center. PBMCs were isolated from 
whole blood by centrifugation through a Ficoll-Hypaque solution (Histopaque-1077, 
Sigma). CD8 cells (T-cytotoxic/suppressor cells) were depleted from the PBMCs by CD8 
Dynabeads (Invitrogen, CA) according to the manufacturer’s instructions. CD8+ T cell-
depleted PBMCs were washed twice in PBS and resuspended in culture media (RPMI 
1640 with 10% FBS, 1!PenStrep and 100 U/mL interleukin-2). Cells were cultured in a 
humidified 5% CO2 incubator at 37°C. 
 
4.2g Flow cytometry analysis of CEM cells 
2!105 CEM cells per well were seeded in 24-well tissue culture plate in 300 µL 
fresh complete medium containing 10% FBS. Before transfection, complexes of Cy3-
labeled siRNA/dendrimer reagents were prepared. The desired amount of siRNA and 
dendrimer reagent was diluted in 50 µL of serum-free medium (Opti-MED), respectively. 
The dendrimer solution was mixed gently and incubated for 10 min at room temperature. 
After the 10-minute incubation, the diluted siRNA and the dendrimer reagent was mixed 
gently and incubated for 30 minutes at room temperature. The 100 µL of 
siRNA/dendrimer complexes was added to each well containing CEM cells and medium. 
Mix gently by rocking the plate back and forth. Incubate the cells at 37°C in a CO2 
incubator for 24 hours, and then the cells were washed three times with 1 mL PBS buffer. 
Cell pellets were resuspended in prewarmed PBS and analyzed by flow cytometry. In this 


case, a commercial reagent TransIT-TKO (Mirus, Madison) was used as control 
according to the manufacturer’s instructions. 
 
4.2h Cellular uptake studies (Fluorescent Microscopy analysis) 
2!105 CEM cells per well were seeded in 24-well tissue culture plate in 300 µL 
fresh complete medium containing 10% FBS. CEM cells were transfected with 50 nM 
Cy3-labeled Tat/Rev Site I siRNA (27 mer) using dendrimer G4 and G5 as above 
described. After 24 hours of post-transfection, the images were collected using a Nikon 
Eclipse TE2000-S fluorescent microscopy system at 40 magnifications.  
Northern Blot analysis of CEM cells and PBMCs. Cells were transfected with 50 
nM Tat/Rev Site I siRNA (27 mer) using dendrimer G4 and G5 as above described. After 
48 hours of post-transfection, the total RNAs were harvested for analysis with STAT-60 
(TEL-TEST “B”, Friendswood, TX) according to the manufacturer’s instructions. Five 
micrograms of total RNAs were electrophoresed in a 15% polyacrylamide-8 M urea gel 
and then transferred to a Hybond N+ membrane (Amersham pharmacia Biotech, USA). 
Prehybridization and hybridization were carried out using PerfectHyb Plus Hybridization 
buffer (Sigma, USA) at 37°C with 3 pmol of a 27-mer DNA oligonucleotide probe end-
labeled with T4 polynucleotide kinase and -32P-ATP. Filters were washed three times at 
37°C for 15 min, prior to autoradiography. We also probed for human U6 snRNA as an 
internal RNA loading standard. In this case, the same siRNA was electroporated into 
CEM cells as system control following the manufacturer’s instructions (Amaxa, MD). 


4.2i Determination of CD4 or TNPO3 gene silencing (qRT-PCR analysis) 
  For CD4 expression, cells were transfected with 50 nM of 21-mer or 27-mer anti-
CD4 siRNA or anti-TNPO3 siRNA using dendrimers as above described. After 48 hours 
of post-transfection, the total RNAs were isolated with STAT-60 (TEL-TEST “B”, 
Friendswood, TX). Expression of the target genes was analyzed by quantitative Real 
time-PCR using 2! iQ SyberGreen Mastermix (BIO-RAD) and specific primer sets at a 
final concentration of 400 nM. Primers were as follows: CD4 forward primer: 5’ – GCT 
GGA ATC CAA CAT CAA GG -3’; CD4 reverse primer: 5’- CTT CTG AAA CCG 
GTG AGG AC -3’; TNPO3 Forward primer: 5’ – CCT GGA AGG GAT GTG TGC -3’; 
TNPO3 Reverse primer: 5’- AAA AAG GCA AAG AAG TCA CAT CA -3’; GAPDH 
forward primer: 5’- CAT TGA CCT CAA CTA CAT G-3’; GAPDH reverse primer: 5’- 
TCT CCA TGG TGG TGA AGA C-3’. 
RNA-Stat60 was used to extract total RNA according to the manufacturer’s 
instruction (Tel-Test). Residual DNA was digested using the DNA-free kit per the 
manufacturer’s instructions (Ambion). cDNA was produced using 2 µg of total RNA 
Moloney murine leukemia virus reverse transcriptase and random primers in a 15 µL 
reaction according to the manufacturer’s instructions (Invitrogen). GAPDH expression 






4.2j HIV-1 challenges and p24 antigen assay   
The CEM cells or PBMCs were infected with HIV IIIB for 5 days (MOI: 0.001). 
Prior to transfection, the infected cells were gently washed with PBS three times to 
remove free virus. 1.0!105 infected cells and 1.0!105 uninfected cells were mixed and 
transfected with 50 nM 27-mer tat/rev siRNA using dendrimers in 24-well plates as 
previously described. The culture supernatants were collected at the 3rd day. The p24 
antigen analyses were performed using a Coulter HIV-1 p24 Antigen Assay (Beckman 
Coulter) according to the manufacturer’s instructions. 
 
4.2k Determination of Tat/rev gene silencing (qRT-PCR analysis) 
For tat/rev gene, cells were infected with HIV-1 IIIB for 5 days (MOI: 0.001). 
Prior to assays, the infected cells were gently washed 3 times to eliminate free virus. 
1.0!105 infected cells and 1.0!105 uninfected cells (total 2!105 per well) were mixed and 
transfected with 50 nM Tat-rev siRNA using dendrimers in 24-well plates as above 
described. After 72 hours of post-transfection, total RNAs were isolated and expression 
of the tat/rev coding RNAs was analyzed by qRT-PCR as previously described. Primers 
were as follows: tat/rev forward primer: 5’- GGC GTT ACT CGA CAG AGG AG -3’; 
tat/rev reverse primer: 5’- TGC TTT GAT AGA GAA GCT TGA TG -3’; GAPDH 
expression was used for normalization of the qPCR data. 
Interferon assay (qRT-PCR analysis). CEM cells were directly treated with 
siRNA/dendrimer complex or IFN-alpha (100 U/mL). After 48 h, total RNAs were 


isolated with STAT-60 (TEL-TEST “B”, Friendswood, TX). Expression of human 
mRNAs encoding p56(CDKL2) and OAS1 were analyzed by quantitative RT-PCR using 
2X iQ SyberGreen Mastermix (BIO-RAD) as described above and specific primer sets 
for these genes at final concentrations of 400 nM. Primers were as follows: P56 (CDKL2) 
forward, 5’-GCC TCC TTG GGT TCG TCT ATA A - 3’; P56 (CDKL2) reverse, 5’-CTC 
AGG GCC CGC TCA TAG TA - 3’; OAS 1 forward, 5’ –GGA GGT TGC AGT GCC 
AAC GAA G - 3’; OAS 1 reverse, 5’-TGG AAG GGA GGC AGG GCA TAA C - 3’. 
GAPDH expression was used for normalization of the qPCR data. 
 
4.2l MTT Cytotoxicity Assay 
The cell viability of siRNAs plus dendrimers on CEM or PBMCs was determined 
by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay (Sigma-
Aldrich, USA). Cells were seeded in each well of 96-well microtiter plates and then 
treated with dendrimer-siRNA complexes. After 48 hour of post-transfection with 
dendrimer-siRNA, cells pellets were collect by centrifuge and replaced fresh medium. 10 
µL MTT solution (5 mg/mL in PBS) was added in each well and then incubated with 
cells for 2 h in the 37°C. After removal of supernatant carefully, the cells were frozen for 
at least 1 h at -80°C. Each well was added 100 µL of DMSO to dissolve the crystals 
properly, the absorbance was measured at the wallack plate reader using Kamings 
protocol for 595 nm. And the viability was expressed as the ratio of absorbance obtained 
from transfected cells to non-transfected cells (n=6). 

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4.2m 5’-RACE PCR assay 
Total RNA (5 µg) from HEK 293 cells transfected with 50 nM experimental 
RNAs (TNPO3 25/27-mer siRNA or scrambled siRNA) in presence of G5 dendrimer was 
isolated using Trizol as manufacture’s protocol. Residual DNA was digested using the 
DNA-free kit per the manufacturer’s instructions (Ambion). Subsequently, total RNA 
was ligated to a GeneRacer adaptor (Invitrogen, Carlsbad, CA) without prior treatment. 
Ligated RNA was reversed transcribed using a gene specific primer 1 (GSP-Rev 1: 5’- 
TCC CGT AAA GAG GCA TGA GAG TCT GT -3’). To detect cleavage products, PCR 
was performed using primers complementary to the RNA adaptor (5’-cDNA primer) and 
gene-specific primer 2 (GSP-Rev 2: 5’- CCG GAT CTG TAA CAA CTG GTC TGA GA 
-3’). Amplification products were resolved by agarose gel electrophoresis and visualized 
by ethidium bromide staining. The specific PCR products were recovered using a 
QIAquick Gel purification Kit and then were cloned into TOPO TA cloning vector pCR 
2.1-TOPO vector (Invitrogen).  Individual clones were identified by DNA sequencing. 
 
In vivo assay: 
4.2n Generation and HIV-1 infection of humanized Rag2-/-c-/- mice (RAG-hu mice) 
 Humanized BALB/c-Rag2-/-c-/- mice were prepared as previously described 
using human fetal liver-derived CD34+ cells. Briefly, neonatal mice were conditioned by 
irradiating at 350 rads and then injected intra-hepatically with 0.5 ~ 1!106 human CD34+ 
cells.  Approximately 12 weeks post-reconstitution, mice were screened for human cell 
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engraftment. Blood was collected by tail bleeds, and red blood cells were lysed using the 
Whole Blood Erythrocyte Lysing Kit (R&D Systems).  The white blood cell fraction was 
stained with antibodies against the human pan-leukocyte marker CD45 (Caltag) and 
FACS analyzed as described. To infect human cell reconstituted RAG-hu mice, HIV-1 
NL4-3 (1.2!105 i.u.) in a 100 µL volume was injected intraperitoneally at least 12 weeks 
after cell engraftment.  Viral loads were examined weekly and viremia was established in 
all the mice by 4 weeks.  
 
4.2o Treatment with dendrimer-siRNA complexes 
G5 dendrimers were diluted to an appropriate concentration in PBS buffer (pH 
7.4) and the experimental siRNAs were diluted with H2O, with all solutions stored at -
20°C. Both solutions were mixed at N/P (= [total end amines in cationic dendrimer] / 
[phosphates in siRNA]) ratio 5 and incubated at 37°C for 30 min in PBS buffer. 
Treatment was done by intravenous (IV) injection on the last day of week 4 with 0.25 
nmol experimental RNAs (4.6 µg cocktailed siRNAs including equal amount of three 
siRNAs: tat/rev siRNA, TNPO3 siRNA and CD4 siRNA, or preparations of G5 
dendrimer-siRNAs conjugates with equal amount of three siRNA portions) in a 40 µL 
volume, followed by another the next day. Later, the injections were continued on a 
weekly basis for 4 weeks. In the second in vivo treatment experiment, 0.25 nmol 
conjugates in a 40 µL volume were administered at 12.5 and 13.5 weeks post last-
infection like above. 
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4.2p Measurement of viral load in plasma 
 To quantify cell-free HIV-1 by qRT-PCR, RNA was extracted from 25 to 50 µL 
of EDTA-treated plasma using the QIAamp Viral RNA kit (QIAGEN). cDNAs were 
produced with Superscript III reverse transcriptase (Invitrogen) using a primer set 
specific for the HIV-1 LTR sequence, and qPCR was performed with the same primer set 
and a LTR specific probe using Supermix UDG (Invitrogen) as described. 
 
4.2q Flow cytometry 
 Whole blood was collected and red blood cells were lysed as reported previously. 
Peripheral blood cells were stained for hCD3-PE and hCD4-PECy5 (Caltag) markers and 
analyzed using a Coulter EPICS XL-MCL FACS analyzer (Beckman Coulter). CD4+ T-
cell levels were calculated as a ratio of the entire CD3 population 
(CD4+CD3+:CD4"CD3+). To establish baseline CD4+ T-cell ratios, all mice were 
analyzed prior to infection. 
 
4.2r Determination of tat/rev siRNA 
At one, three and nine weeks post-injection, blood samples were collected and 
small RNAs were isolated with MirVana miRNA isolation Kit (Applied Biosystems) 
according to the manufacturer’s instruction.  The siRNA quantification was performed 
using TaqMan MicroRNA Assay according to manufacturer’s recommended protocol 
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(Applied Biosystems).  10 nanograms of small RNA, 0.2 µM stem-loop RT primer, RT 
buffer, 0.25 mM dNTPs, 3.33 units/mL MultiScribe reverse transcriptase (RT) and 0.25 
units/mL RNase inhibitor were used in 15 µL RT reactions for 30 min at 16°C, 30 min at 
42°C, and 5 min at 85°C, using the TaqMan MicroRNA reverse transcription Kit 
(Applied Biosystems).  For real-time PCR, 1.33 µL of cDNA, 0.2 mM TaqMan Probe, 
1.5 mM forward primer, 0.7 mM reverse primer, and TaqMan Universal PCR Master 
Mix were added in 20 µL reactions for 10 min at 95°C and 40 cycles of 15 sec at 95°C 
and 1 min at 60°C.  All real-time PCR experiments were done using an iCycler iQ system 
(Bio-Rad).  Primers were as follows: Site I Looped RT primer: 5’- GTC GTA TCC AGT 
GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACA CAG CG -3’; Site I 
Forward Primer:  5’- GCT GAT GAG CTC TTC GTC G - 3’; Site I Reverse Primer:  5’- 
GTG CAG GGT CCG AGG T - 3’; Site I probe primer: 5’- 6- FAM- TCG CAC TGG 
ATA CGA CAC AGC GAC GA –BHQ1 -3’.  In this case, a synthetic 27 mer duplex 
RNA was used as positive control. 
 
4.2s Determination of targeted genes expression.  
Human PBMCs were obtained from treated mice at one and three weeks post-
injection and total RNAs were isolated with STAT-60 (TEL-TEST “B”) according to the 
manufacturer’s instructions.  Residual DNA was digested using the DNA-free kit per the 
manufacturer’s instructions (Ambion). cDNA was made using 2 µg of total RNA. 
Reverse transcription was carried out using Moloney murine leukemia virus reverse 
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transcriptase and random primers in a 15 µL reaction according to the manufacturer’s 
instructions (Invitrogen).  Expression of the tat/rev coding RNAs was analyzed by 
quantitative RT-PCR using 2! iQ SyberGreen Mastermix (BIO-RAD) and specific 
primer sets at a final concentration of 400 nM. Gapdh expression was used for 
normalization of the qPCR data.  Primers were as follows: IIIB or NL4-3 tat/rev forward 
primer: 5’- GGC GTT ACT CGA CAG AGG AG -3’; IIIB or NL4-3 tat/rev reverse 
primer: 5’- TGC TTT GAT AGA GAA GCT TGA TG -3’; CD4 forward primer: 5’ – 
GCT GGA ATC CAA CAT CAA GG -3’; CD4 reverse primer: 5’- CTT CTG AAA 
CCG GTG AGG AC -3’; TNPO3 Forward primer: 5’ - CCT GGA AGG GAT GTG TGC 
-3’; TNPO3 Reverse primer: 5’- AAA AAG GCA AAG AAG TCA CAT CA -3’; gapdh 
forward primer 1: 5’- CAT TGA CCT CAA CTA CAT G-3’; gapdh reverse primer 2: 5’- 
TCT CCA TGG TGG TGA AGA C-3’. 
 
4.2t Interferon assays  
Total RNA was isolated from PBMCs of treated mice using STAT-60. Expression 
of mRNAs encoding p56(CDKL2) and OAS1 were analyzed by quantitative RT-PCR 
using 2! iQ SyberGreen Mastermix (BIO-RAD) as described above and specific primer 
sets for these genes at final concentrations of 400 nM.  Primers were as follows: P56 
(CDKL2) forward, 5’- TCA AGT ATG GCA AGG CTG TG -3’; P56 (CDKL2) reverse, 
5’- GAG GCT CTG CTT CTG CAT CT -3’; OAS1 forward, 5’ - ACC GTC TTG GAA 
CTG GTC AC -3’; OAS1 reverse, 5’- ATG TTC CTT GTT GGG TCA GC -3’; gapdh 
expression was used for normalization of the qPCR data.  To measure any induced IFN-" 
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directly, Human IFN-"1 ELISA Ready-SET-Go! (eBioscience) was used.  Mice were 
injected with G5 dendrimer mutant tat/rev dsiRNA complex, dsiRNA alone, G5 
dendrimer alone, G5 dendrimer-siRNA tat/rev, or G5 dendrimer-cocktail. At 2 and 24 
hours post treatment 25-50 µL of EDTA-treated plasma was collected from 3 mice per 
treatment group and from 3 positive control mice intravenously injected with 5 µg of 
poly (I:C) (Sigma) in a 50 µL volume.  Plasma was evaluated as per instructions supplied 
in the kit.   
 
4.2u Statistical Methods  
The mouse viral loads and CD4:CD3 T-cell ratios were plotted by using a lowess 
smoother across values. Viral loads were first log-transformed prior to smoothing and 
then anti-transformed for plotting.  Missing values were imputed with a last observation 
carried forward scheme. The calculations were conducted as previously described (207).  
 
4.3 Results 
4.3a Dendrimer-siRNAs form stable nanoscale complexes which protect the siRNAs 
from serum nucleases and facilitate siRNA delivery into human T-cells in vitro 
The polycationic vectors must form stable, nanometer-scale complexes with 
negatively charged siRNAs to ensure protection from serum ribonucleases and provide 
efficient delivery to cells and tissues via endocytosis. The TEA-core PAMAM dendrimer 
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of generation 5 (G5) formed stable complexes with the 27-mer Dicer substrate tat/rev 
siRNA (dsiRNA), resulting in complete gel retardation of the dsiRNA at an N/P (total 
terminal amines in the cationic dendrimer / phophates in the siRNA) ratio # 2. We next 
used transmission electron microscopy (TEM) to analyze the size and morphology of the 
dendrimer G5-dsiRNA complexes at a N/P ratio of 5. The TEM results show well-
condensed spherical particles with diameters of ~ 100 nm a size which favors efficient 
endocytosis-mediated cell uptake. The stable G5-siRNA nanoparticles at an N/P ratio of 5 
protected the dsiRNA from RNase degradation, even after 90 min exposure to RNase. In 
contrast, the uncomplexed, naked dsiRNA was rapidly degraded within 10 minutes of 
RNase incubation. 
Flow cytometry and fluorescent microscopy were carried out to analyze the 
cellular uptake of the G5-dsiRNA complexes. Cy3-labeled dsiRNAs were complexed 
with the G5 dendrimer and the complex was added to HEK293 cells (an adherent cell 
line) or human T-lymphoblast CCRF-CEM cells (a suspension cell line). For comparison 
purposes, the same cell lines were transfected with the Cy3-labeled dsiRNAs using 
commercial lipid based transfection agents. Flow cytometry analyses conducted 24 hours 
after transfection with HEK293 cells indicated that the G5 dendrimer mediated cellular 
uptake of Cy3-dsiRNA approached 60% at the tested concentration of 10 nM, whereas 
only ~15% uptake was obtained with the commercial lipid based carrier.  The cellular 
uptake of the dendrimer-Cy3-dsiRNA complexes was dose dependent. Similarly, 
fluorescence microscopic imaging revealed efficient delivery of the Cy3-dsiRNA to the 
suspension CEM T-cells cells, with an efficiency comparable to a commercial lipid based 
reagent. No uptake was observed when uncomplexed Cy3-dsiRNAs were tested.  
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Figure 4.2: Dendrimer-dsiRNA nanoparticles mediate specific gene silencing in vitro. Inhibition of CD4 expression by 
dendrimer G5-mediated delivery of 21-mer or 27 mer anti-CD4 siRNAs (at an N/P ratio of 5) was assayed using qRT-
PCR two days post-treatment in culture (a) CEM T-cells and (b) human PBMCs. Dendrimer-siRNA complexes inhibit 
HIV-1 infection in (c) CEM T-cells and (d) human PBMCs previously infected with HIV-1. HIV-1 infected cells were 
incubated at 37°C with the G5-27-mer anti-tat/rev dsiRNA complexes or G5-cocktail siRNAs (combination of 27-mer 
anti-tat/rev dsiRNA and anti-CD4 dsiRNA) complexes. The culture supernatants were collected at 3 day following 
addition of the complexes for HIV p24 antigen analyses. Data represent the average of triplicate measurements of p24 
and the average of three replicates. 
 
As a further confirmation of the cellular uptake of the G5 dendrimer-siRNA 
complex, we carried out live-cell confocal microscopy using HeLa cells and a G5 
dendrimer diRNA complex. These analyses demonstrated that the G5 dendrimer 
complexed with the Alexa488 labeled dsiRNA was effectively internalized (Figure 
S4.1A). No green fluorescence was observed when the cells were incubated with 
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uncomplexed dsiRNA (data not shown). To further evaluate the mechanism of 
dendrimer-mediated siRNA delivery, we tested different endocytic inhibitors (Figure 
S4.1). No significant effects on uptake were observed when Genistein (a caveolae-
mediated endocytosis inhibitor) or Chloropromazine (a Clathrin-mediated endocytosis 
inhibitor) were used. However, an increasing concentration of cytochalasin D (a 
macropinocytosis inhibitor) reduced the cellular uptake of the dendrimer-siRNA 
complex, suggestive of a cell uptake mechanism involving macropinocytosis (Figure 
S4.1).  
 
4.3b dsiRNAs are  released from the dendrimer complexes and mediate specific gene 
silencing in vitro 
 TNPO3 and CD4 are HIV-1 host dependency factors that are potential 
therapeutic targets (212, 213). CD4 is the primary receptor for HIV-1, and transient 
knocking down of this receptor blocks HIV-1 infection (208, 209). TNPO3 is a cellular 
factor that is involved in facilitating the cytoplasmic to nuclear trafficking of the HIV-1 
pre-intergration complex and was shown by a siRNA screen to block HIV-1 infection at 
the afferent stage (209). We therefore asked whether the G5 dendrimer delivered 
dsiRNAs targeting transcripts encoding these proteins effectively mediated gene 
silencing in human T-lymphoblast CEM cells. The siRNA mediated knockdowns of the 
target transcripts were evaluated via quantitative real-time PCR (qRT-PCR). The G5 
dendrimer delivered anti-CD4 dsiRNA complex resulted in a 75% decrease in CD4 
mRNA levels 48 hours post-transfection (Figure 4.2C). The dendrimer G5 delivered 
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dsiRNA gave somewhat better target knockdown than the corresponding conventional 
19+2 mer siRNA. In similarity to the CD4 knockdown results, the G5 dendrimer 
delivered dsiRNA targeting TNPO3 resulted in somewhat better target knockdown than 
the 19+2 siRNA (Figure S4.2). These data confirm previous reports of enhanced efficacy 
when dsiRNAs are used (210).  
Figure 4.3: Dendrimer-dsiRNA complexes suppress viral loads in HIV-1 infected RAG-hu mice. HIV-1 viral 
loads at different weeks post infection and treatment are indicated. The treatment period is indicated by the yellow 
framed in region. Viral loads at each indicated week pre- and post-treatment. Weeks post-injection and the time point 
of treatment start and end are indicated. (a) The first-treatment included five weekly injections: The viral loads of 
uninfected mice (n = 2), non-treated mice (n = 7), naked cocktail dsiRNA treated mice (n = 5), G5-mutant-tat/rev 
dsiRNA complex treated mice (n = 3), G5-tat/rev dsiRNA complexes treated mice (n = 6) and G5-cocktail siRNA 
complex treated mice (n = 6) are indicated. (b) The re-treatment including twice weekly injections with G5-cocktail 
siRNA complexes: The viral loads of uninfected mice (n = 2), non-treated mice (n = 4), G5-tat/rev dsiRNA complex 
treated mice (n = 5) and G5-cocktail dsiRNA complex treated mice (n = 1) are indicated. P values for both experiments 
were determined as described in Materials and Methods. The viral RNA was detected through qRT-PCR as described 
in Methods.  If there was no detectable viral RNA we established this as a value of 1 (100) to allow for the use of 
logarithmic values on the Y-axis. 
 
Since the dsiRNAs are cleavage substrates Dicer, we asked whether the dendrimer 
G5 delivered dsiRNAs were processed into 21-23 base siRNAs in CEM cells. Northern 
blotting analyses (Figure S4.3) demonstrated both unprocessed 27 mer dsiRNAs as well 
as processed 21-22 mer siRNAs in the transfected cells.  
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We next evaluated target knockdown directed by dsiRNAs delivered with the G5 
dendrimer into primary human peripheral blood mononuclear cells (PBMCs). Primary 
PBMC-CD8 depleted CD4+ cells were incubated with the G5 dendrimer anti-CD4 
dsiRNA complex for 48 hours, and the CD4 mRNA levels were subsequently monitored 
by qRT-PCR (Figure 4.2D). The G5 dendrimer delivered dsiRNA resulted in ~ 60% 
knockdown of the levels of the CD4 mRNA at the tested concentration of 50 nM. In 
contrast, no inhibition was observed with G5 dendrimer alone or G5 dendrimer delivered 
scrambled dsiRNA.  
To validate that the G5 dendrimer delivered dsiRNAs were functioning through 
the RNAi mechanism, we carried out a modified 5’-RACE (Rapid amplification of 
cDNA end) on total RNAs isolated from control and G5 dendrimer delivered anti-TNPO3 
dsiRNA in CEM cells. For these analyses we used the Ago2 cleavage specificity which 
takes place between bases 10 and 11 relative to the 5’ end of the guide strand siRNA 
(211, 212). RACE PCR product sequence analyses should reveal a linker addition on the 
siRNA complementary target at the base 10 nucleotides downstream from the 5’ end of 
the antisense siRNA strand.  We obtained PCR bands of the predicted length for a Dicer 
processed siRNA directed cleavage product following nested PCR reactions (Figure 
S4.4). No appropriately sized products were generated from total RNAs prepared from 
cells treated with a G5 dendrimer scrambled dsiRNA treated cells. The PCR amplified, 
gel-purified bands of the predicted lengths were cloned and the individual clones 
characterized by DNA sequencing. The results obtained showed that the cleavage 
reaction took place at the predicted position for the Dicer processed dsiRNA between 
positions 10 and 11 from the 5’ end of the predicted dicer processed siRNA antisense 
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strand. Based upon the position of the cleavage site these results also reconfirm Dicer 
processing of the dsiRNA to 21-23 base siRNAs (as shown in Figure S4.4). 
We next investigated whether the G5 dendrimer delivered siRNAs triggered type I 
interferon responses.  The levels of two different type I interferon stimulated mRNAs 
were quantified by quantitative RT-PCR (Figure S4.5 A, B). From these data we 
concluded that the G5 dendrimer delivered dsiRNA complex did not activate the type I 
interferon pathways (Figure S4.5 C, D).  
 
4.3c The G5 dendrimer -delivered dsiRNAs inhibit HIV-1 infection of CEM T-cells 
and human PBMCs 
Having established that the G5 dendrimer delivered anti-HIV dsiRNAs effectively 
downregulated the cellular CD4 and TNPO3 targets, we next assessed the anti-HIV-1 
activity of the dendrimer G5-delivered dsiRNAs (172, 173); In these assays the G5 
dendrimer dsiRNA complexes were incubated with cells that had been previously 
infected with HIV-1 IIIB followed by assays for the HIV-1 encoded p24 peptide as 
previously reported (172, 173).  The results presented in Figure 4.2 A and B show the 
HIV-1 p24 antigen levels following treatment with the G5 dendrimer-siRNA complexes. 
The HIV-1 p24 production in CEM cells and PBMC-derived CD4+ cells was reduced 
approximately three fold 72-hours post-transfection. Since these experiments were 
carried out in cells which were previously infected with HIV-1 the dsiRNAs cannot 
completely eliminate p24 production. When two dsiRNAs targeting CD4 and the HIV-1 


encoded tat/rev transcripts were combined, the G5 dendrimer-combinatorial siRNA 
complex provided strong inhibition of HIV-1 replication and spread in PBMC-CD4+ 
cells. 
To validate the RNAi efficacy in these experiments, we evaluated the down-
regulation of HIV-1 tat/rev gene expression following treatment of CEM cells with the 
G5 dendrimer anti-tat/rev dsiRNA complex. The expression levels of tat/rev encoding 
RNAs were determined by quantitative RT-PCR analysis three days post-treatment of 
cells with the complex. Substantial down regulation of the tat/rev mRNA was observed, a 
direct consequence of the G5 dendrimer-anti-tat/rev siRNA delivery. In contrast, 
treatment of infected cells with the empty dendrimer or siRNA alone had no affect HIV 
tat/rev levels (Figure 4.2A and B).  
 
4.3d Systemic administration of the G5 dendrimer-dsiRNA complexes suppresses 
HIV-1 viral loads in viremic RAG-hu mice 
Given the promising results of the G5 dendrimer mediated dsiRNA delivery in 
CD+ T cells, we next sought to determine if the dendrimer-siRNA complexes could 
functionally deliver dsiRNAs in vivo and provide protection and/or inhibition of HIV-1 
infection in humanized mice. RAG-hu
 
mice were first infected with HIV-1 NL4-3 by 
intraperitoneal (IP) injection until they became viremic, usually 3 weeks post infection. 
The viral loads in these animals averaged 105 viral RNA particles per mL. These viremic 
mice were subsequently given weekly intravenous (IV) injections of dendrimer G5-


dsiRNA complexes as described in the methods section. As control groups, animals were 
administered a G5 dendrimer mutant tat/rev dsiRNA complex, dsiRNA alone or G5 
dendrimer alone.   
Plasma RNA viral levels were monitored by qPCR on a weekly basis. There were 
six animals in each treatment group. The siRNA treatment groups consisted of dendrimer 
complexed with 0.25 nmols of the anti-tat/rev dsiRNA or 0.25 nmols of a combination of 
the anti-tat/rev, anti-CD4 and anti-TNPO3 dsiRNAs (Figure 4.3A). We observed a 
general pattern of decreased viral loads in the majority of the G5 dendrimer treated mice 
when the functional dsiRNAs were applied (weeks 8-12 as shown). The suppression of 
viral loads was on average three logs relative to the controls and these reductions reached 
statistical significance with a rank sum P = 0.0002 (Figure 4.3A). Even three weeks 
following the termination of the treatment, viral loads were still suppressed in the 
majority of treated animals (weeks 13-15), indicating a prolonged antiviral effect in these 
animals. Importantly, there was no viral suppression in the animals treated with the G5 
demdrimer delivered mutant tat/rev dsiRNA complex (Figure 4.3) or the G5 dendrimer 
alone (Figure S4.6).  
Comparison of the inhibitory activity afforded by a single anti-HIV tat/rev 
dsiRNA versus a combination of three dsiRNAs targeting HIV-1 tat/rev and the HIV 
dependency factors (HDFs) CD4 and TNPO3 showed that the combinatorial complex 
provided more effective inhibition of HIV-1 than the single anti-tat/rev dsiRNA when 
viral loads were analyzed from the second through the fifth weeks of treatment. 
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Although viral levels remained lower in animals treated with the functional G5 
dendrimer-dsiRNAs three weeks following the termination of treatment, these levels 
continued to slowly rise. We asked if re-treatment with the G5 dendrimer-dsiRNA 
complexes could restore suppression of viral levels. At three months following the last 
administration of the initial treatment, G5 dendimer cocktail of dsiRNAs was re-
administered to verify efficacy of re-treatment. The re-treatments were conducted at 
weeks 24.5 and 25.5 post infection as shown (Figure 4.3B). These re-treatments resulted 
in a statistically significant (P=0.0492) re-inhibition of HIV-1 levels (Figure 4.3B). 
Complete suppression persisted for 3 weeks beyond the re-treatment period in the G5 
dendrimer-cocktail dsiRNA treated mice.  
In efforts to further evaluate the effectiveness of the dendrimer mediated dsiRNA 
delivery, we assessed the intracellular levels of the delivered dsiRNAs. Taqman qPCR 
assays were carried out to quantify the tat/rev dsiRNA levels in cells collected from 
peripheral blood collected at various times during and after treatment. The results 
presented in Figure 4.4A reveal that the tat/rev dsiRNA was quantifiable in all of the G5 
dendrimer dsiRNA treated mice at two weeks into the treatment period (week 9) and even 
at two weeks following the last injection (week 13), the dsiRNAs were still detectable in 
cells prepared from all the dendrimer-dsiRNA treated mice (Figure 4.4B). No dsiRNAs 
were detected in the cellular fractions from mice treated with naked dsiRNAs. 
We next evaluated the sequence specific gene silencing in the HIV-1 infected 
Rag-Hu mice. The relative levels of reduction of the three targeted genes (HIV tat/rev, 
CD4 and TNPO3) in PBMCs of treated mice were evaluated by quantitative real-time 
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PCR. The G5 dendrimer-dsiRNA treated mice had reduced levels of the corresponding 
targeted mRNA levels relative to the controls following the first and second treatments 
with the  G5 dendrimer -dsiRNA complexes (weeks 8 and 9) (Figure 4.4C and D). 
 
4.3e The G5 dendrimer-dsiRNA treatment protects against HIV-1 mediated T-cell 
depletion.   
HIV-1 infection characteristically results in a progressive loss of helper CD4+ T 
cells. During the course of infection, CD4+ T cell levels fall transiently during the acute 
stage of infection followed by a return to a set point for several months/years with an 
eventual depletion leading to AIDS (186, 187). The levels of CD4+ T-cells show similar 
declines in the HIV-1 infected humanized mice (56). Considering the siRNA mediated 
suppression of HIV-1 viral replication in the G5 dendrimer -dsiRNA treated animals; we 
sought to determine whether the reduced viral loads impacted on the T-cell levels of the 
treated animals. To determine this, we monitored the levels of CD4+ T-cells in peripheral 
blood collected at different times post-treatment (Figure 4.5). In uninfected mice, the 
levels of CD4+ T cells remained stable (within a 10% variation range) throughout the 
course of the experiments. For those animals treated with the tat/rev or combination 
dsiRNAs, the protection against T-cell depletion reached statistical significance (P = 
0.0562) (Figure 4.5). In contrast, in the animals that were HIV-1 infected but not 
receiving treatment, the viral infection resulted in a rapid decline in CD4+ T cells 
beginning at week 4 post infection, falling to below 40% of the starting levels at 20 













Figure 4.4: The detection and function of siRNAs in blood cells of HIV-1 infected RAG-hu mice and in vivo 
biodistribution. (a, b) Detection of the tat/rev siRNA sequences at weeks 9 and 13 post-infection usin  naked siRNAs 
versus G5-dsiRNA complex treated animals from Figure 3a.  The background copy number of siRNA is <10
7 (gray).  
Error bars indicate SD (n = 4). (c, d) Expression levels of targeted tat/rev, CD4 and TNPO3 gene transcripts at weeks 8 
and 9 post infection are shown relative to HIV-1 infected, non-treated animal samples (c) and naked siRNA treated 
animal samples (d), respectively. (e) In vivo biodistribution analyses. The delivery of the anti- tat/rev siRNA was 
monitored using Taqman qRT-PCR on RNAs isolated from various tissues and PBMCs following systemic 
administration of the G5 dendrimer-dsiRNA nanoparticles in RAG-hu mice. The background copy number of siRNA is 




There was no protection in the mice treated with the G5 dendrimer -mutant tat/rev 
dsiRNA complex (Figure 4.5) or the empty G5 dendrimer (Figure S4.5). In animals 
treated with the G5 dendrimer-cocktail of dsiRNAs the levels of CD4+ T cells remained 
stable well beyond the last treatment.  
Figure 4.5: Dendrimer-dsiRNA complexes protect RAG-hu mice from CD4+ T-cell loss.  CD4+ T-cell levels were 
assessed by FACS at each indicated week pre- and post-siRNA treatment. Start and end of treatments are indicated by 
the yellow framed in region. Mice from the first treatment depicted in Figure 3a. Uninfected mice (n = 2), non-treated 
mice (n = 7), G5-mutant-tat/rev dsiRNA complex treated mice (n = 3), G5-tat/rev dsiRNA complex treated mice (n = 6) 
and G5-cocktail dsiRNA complex treated mice (n = 6) are indicated. P values for the experiment are indicated and were 
determined as described in Materials and Methods. BL (base line): each individual mouse was bled two times prior to 
HIV-1 infection and the CD4:CD3 levels were averaged within treatment groups to establish a baseline CD4:CD3 
level.  
 
4.3f The G5 dendrimer-mediated dsiRNA delivery does not trigger type I interferon 
responses in vivo 
It has been previously reported that synthetic siRNAs delivered by liposomes or 
other polymers can trigger innate immune responses, such as Toll-like receptor (TLR) 
mediated induction of type I interferon (IFN), tumor necrosis factor-alpha (TNF-") and 
interlecukin-6 (IL-6) (211). We therefore assessed whether or not treatment of the 
animals with the G5 dendrimer-dsiRNAs resulted in induction of type I IFN–regulated 
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gene expression. To assay for this we used quantitative RT-PCR expression assays on 
PBMC derived RNAs isolated from the G5 dendrimer-dsiRNA treated animals as well as 
controls. IFN-" treated PBMCs was used as a positive control to confirm up-regulation 
of p56 and OAS1 gene expression. No significant differences in IFN responsive gene 
expression were discernable in samples from either the treated or control animals at 
different times post-treatment (Figure 4.6A and B). Using an ELISA assay we also 
directly monitored IFN-" levels in treated mice at 2 hours and 24 hours post-injection of 
the experimental RNAs and found no significant elevation of IFN- (Figure 4.6C).  
Since microRNA levels can be perturbed via competition with the exogenously 
introduced siRNAs, we therefore monitored PBMC encoded microRNA miR21 
expression levels by Taqman assays on RNAs prepared from cells isolated from animals 
receiving the dendrimer delivered dsiRNAs versus samples from the control animals. 
Figure S4.6 depicts the results, which show no perturbation of miR-21 levels in the 





Figure 4.6: In vivo administration of dendrimer-dsiRNA complexes do not induce interferon or toxicities.  (a, b) 
The expression of type I interferon response genes (P56 and OAS1) at week 8 (a) and 9 (b) post infection after 
treatment with siRNAs and G5-dsiRNA complexes.  IFN-  treated, HIV-1 infected human PBMCs were used as a 
positive control.  Gene expression was normalized to the gapdh mRNA.  Error bars indicate SD (n = 4).  (c) The 
expression levels of IFN- at 2 hours or 24 hours post G5-dsiRNA nanoparticle injections as measured by an ELISA 
are shown. Poly (I:C) treated infected Rag-hu mice were used as a positive control. Error bars indicate SD (n = 3). (d) 
The levels of LDH (lactate dehydragenase) post G5-dsiRNA nanoparticles injections are shown. Cellular lysate treated 







Recent studies have demonstrated that applications of siRNAs targeting viral or 
cellular transcripts provide inhibition of HIV-1 replication in vitro and in vivo. Cell-type-
specific delivery of siRNAs to primary T cells in humanized mice has been accomplished 
via the use of a CD7 specific antibody. Although the use of antibody mediated targeted 
delivery is appealing there are potential cost and production issues for preparing the 
siRNA complexed antibodies as well as potential problems of immunogenicity. On the 
other hand, synthetic vehicles such as dendrimers can be synthesized with controlled and 
defined structures, are amenable to chemical modification, stable in biological fluids and 
are not immunogenic. Importantly, an ideal siRNA delivery system for treatment of HIV-
1 infection should have the capacity for combining siRNAs to different targets, both viral 
and cellular, to avert viral escape mutants. 
We have tested a PAMAM generation 5 dendrimer-dsiRNA delivery system for 
the treatment of HIV-1 infection both in cell culture and in a humanized mouse model. In 
the mouse model the animals are first infected with HIV-1 until they become viremic, 
and are subsequently treated with the dendrimers-dsiRNAs to model how a treatment 
might be structured for human applications. Dendrimers are a class of structurally highly 
branched and well-defined synthetic polymers. The dendrimer used in this study is a fifth 
generation dendrimer (G5) that contains 96 terminal amine groups on the surface and a 
TEA core with a flexible structure. They are able to form stable and uniformly sized 
complexes with nucleic acids via electrostatic interactions, and the flexible structure 
further enhances the interaction with nucleic acids through mutually induced fit. By 
simply mixing the G5 dendrimer with siRNAs, stable nanometer-scale (ca 100 nM 
diameter) particles were formed. Following internalization in cells via macropinocytosis, 


the G5 dendrimer-dsiRNA complexes release the dsiRNAs, which are subsequently 
processed by Dicer into 21-23 base siRNAs that trigger sequence specific gene silencing 
of the targeted mRNAs.  
In this study we provided data demonstrating that a cocktail of three dsiRNAs 
targeting HIV-1 tat/rev and two cellular targets, CD4 and TNPO3 resulted in down-
regulation of all three targeted transcripts in vivo. The inhibition of these targets resulted 
in a reduction of the viral RNA load and protection of CD4+ T cells from HIV-1 
mediated depletion. Furthermore the results of this study demonstrate that a combination 
of dsiRNAs can be functionally delivered to T-lymphocytes in vivo in the absence of any 
apparent or measured toxicity. Importantly, we also show 3 months after we stopped the 
first treatments-allowing viral loads to become elevated again, animals were re-treated 
with the dendimer- cocktail dsiRNA, resulting once again in strong inhibition of HIV-1. 
This suppression persisted for an additional 3 weeks beyond the re-treatment period. 
Collectively, our results demonstrate the capacity of the G5 dendrimer delivered dsiRNAs 
to achieve marked viral suppression in vivo, resulting in protection of CD4 T cells from 
HIV-1 mediated depletion. Given the importance and challenge of siRNA delivery, it is 
of significance that these results provide the first demonstration of nano-particle mediated 
delivery of siRNAs to hematopoietic cells in vivo, and provide the impetus for further 
clinical development of this strategy. The data presented also support the use 
combinatorial multi-targeting dsiRNAs for treating HIV-1 infection as a standalone 
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Therapeutic strategies designed to treat HIV infection with combinations of 
antiviral drugs have proven to be the best approach for slowing the progression to AIDS. 
Despite this progress, there are problems with viral drug resistance and toxicity, 
necessitating new approaches to combating HIV-1 infection. We have therefore 
developed a different combination approach for the treatment of HIV infection in which 
an RNA aptamer, with high binding affinity to the HIV-1 envelope (gp120) protein and 
virus neutralization properties, is attached to and delivers a small interfering RNA 
(siRNA) that triggers sequence-specific degradation of HIV RNAs. We have tested the 
antiviral activities of these chimeric RNAs in a humanized Rag2(-/-)c(-/-) (RAG-hu) 
mouse model with multilineage human hematopoiesis. In this animal model, HIV-1 
replication and CD4(+) T cell depletion mimic the situation seen in human HIV-infected 
patients. Our results show that treatment with either the anti-gp120 aptamer or the 
aptamer-siRNA chimera suppressed HIV-1 replication by several orders of magnitude 
and prevented the viral-induced helper CD4(+) T cell decline. In comparison to the 
aptamer alone, the aptamer-siRNA combination provided more extensive inhibition, 
resulting in a significantly longer antiviral effect that extended several weeks beyond the 
last injected dose. The aptamer thus acts as a broad-spectrum HIV-neutralizing agent and 
an siRNA delivery vehicle. The combined aptamer-siRNA agent provides an attractive, 






5.2 Materials and methods 
5.2a Reagents 
Unless otherwise noted, all chemicals were purchased from Sigma-Aldrich, all 
restriction enzymes were obtained from New England BioLabs (NEB) and all cell culture 
products were purchased from GIBCO (Gibco BRL/Life Technologies, a division of 
Invitrogen.). Sources for the other reagents were: DuraScribe T7 transcription Kit 
(EPICENTRE Biotechnologies); Silencer siRNA Labeling Kit (Ambion); Hoechst 33342 
(nuclear dye for live cells) (Molecular Probes, Invitrogen); Random primers (Invitrogen); 
SuperScript III RT kit (Invitrogen); Bio-Spin 30 Columns (Bio-Rad); CHO-Env 
Transfectants (CHO-WT and CHO-EE), the HIV-1 NL4-3 and HIV-1 BaL viruses, and 
clinical isolates (X4-strain: HIV-1 92UG021; R5-strain: HIV-1 RU570 and HIV-1 
98CN009) were obtained from the AIDS Research and Reference Reagent Program. 
 
5.2b Generation of aptamer-siRNA chimera RNA (Ch A-1) by in vitro transcription 
The design, synthesis and in vitro efficacies of the aptamer A-1 and aptamer-
siRNA conjugates have been described in detail previously (156).  SiRNA Dicer 
substrate sense, antisense strand RNAs and DNA oligonucleotides were purchased from 
Integrated DNA Technologies (IDT). 
Tat/rev Site I 27 mer siRNA: 
Sense strand: 5’- GCG GAG ACA GCG ACG AAG AGC UCA UCA -3’  
Antisense strand: 5’- UGA UGA GCU CUU CGU CGC UGU CUC CGC dTdT-3’ 


Aptamer A-1: 5- GGG AGG ACG AUG CGG AAU UGA GGG ACC ACG CGC UGC 
UUG UUG UGA UAA GCA GUU UGU CGU GAU GGC AGA CGA CUC GCC CGA 
-3  
Chimera A-1-sense strand: 5’- GGG AGG ACG AUG CGG AAU UGA GGG ACC 
ACG CGC UGC UUG UUG UGA UAA GCA GUU UGU CGU GAU GGC AGA CGA 
CUC GCC CGA UU GCG GAG ACA GCG ACG AAG AGC UCA UCA  -3’ 
Chimera A-5-sense strand: 5’- GGG AGG ACG AUG CGG GAA ACU AGU UUG 
AAU AAU GGU GUA GAG GAG GGU CAA UAG UUU CGU UGG UGC AGA CGA 
CUC GCC CGA UU GCG GAG ACA GCG ACG AAG AGC UCA UCA -3’ 
Antisense strand: 5’- UGA UGA GCU CUU CGU CGC UGU CUC CGC dTdT-3’   
The sense strands of the chimeras are underlined.  The italic UU is the linker between the 
aptamer and siRNA portions.  The assembly of these chimeric constructs was described 
previously (156) and a schematic is presented in Fig 5.1. 
 
5.2c Generation and HIV-1 infection of humanized Rag2-/-c-/- mice (RAG-hu mice) 
Humanized BALB/c-Rag2-/-c-/- mice were prepared as previously described (56) 
using human fetal liver-derived CD34+ cells.  Briefly, neonatal mice were conditioned by 
irradiating at 350 rads and then injected intra-hepatically with 0.5 ~ 1!106 human CD34+ 
cells.  Approximately 12 weeks post-reconstitution, mice were screened for human cell 
engraftment. Blood was collected by tail bleeds, and red blood cells were lysed using the 
Whole Blood Erythrocyte Lysing Kit (R&D Systems).  The white blood cell fraction was 
stained with antibodies against the human pan-leukocyte marker CD45 (Caltag) and 
FACS analyzed as described (56).  To infect human cell reconstituted RAG-hu mice, 


HIV-1 NL4-3 (1.2!105 i.u.) in a 100 µL volume was injected intraperitoneally at least 12 
weeks after cell engraftment.  Viral loads were examined weekly and viremia was 
established in all the mice by 3 weeks.  Treatment was done by intravenous (IV) injection 
on the last day of week 4 with 0.25 nmol experimental RNAs (4.6 µg tat/rev siRNA, or 
11.3 µg Ch A-1) in a 40 µL volume, followed by another the next day.  Later, the 
injections were continued on a weekly basis for 4 weeks.  In the second in vivo treatment 
experiment, 0.25 nmol each of Mutant Chimera Ch A-5, Aptamer alone A-1 or Aptamer-
siRNA chimera Ch A-1 in a 40 µL volume were administered at 5 weeks post infection 
like above and continued only for 3 weekly injections. 
 
5.2d Measurement of viral load in plasma 
To quantify cell-free HIV-1 by qRT-PCR, RNA was extracted from 25 to 50 µL 
of EDTA-treated plasma using the QIAamp Viral RNA kit (QIAGEN).  cDNAs were 
produced with Superscript III reverse transcriptase (Invitrogen) using a primer set 
specific for the HIV-1 LTR sequence, and qPCR was performed with the same primer set 
and a LTR specific probe using Supermix UDG (Invitrogen) as previously described 
(56). 
 
5.2e Flow cytometry 
Whole blood was collected and red blood cells were lysed as reported previously 
(44 55). Peripheral blood cells were stained by hCD3-PE and hCD4-PECy5 (Caltag) 
antibodies and analyzed using a Coulter EPICS XL-MCL FACS analyzer (Beckman 
Coulter). CD4+ T-cell levels were calculated as a ratio of the entire CD3 population 


(CD4+CD3+:CD4"CD3+). To establish baseline CD4+ T-cell ratios, all mice were 
analyzed prior to infection. 
 
5.2f Detection of tat/rev siRNA 
At five, seven and twelve weeks post-infection (one, three and nine weeks post-
injection), blood samples were collected and small RNAs were isolated with MirVana 
miRNA isolation Kit (Applied Biosystems) according to the manufacturer’s instruction.  
The siRNA quantification was performed using TaqMan MicroRNA Assay according to 
manufacturer’s recommended protocol (Applied Biosystems).  10 nanograms of small 
RNA, 0.2 µM stem-loop RT primer, RT buffer, 0.25 mM dNTPs, 3.33 units/mL 
MultiScribe reverse transcriptase (RT) and 0.25 units/mL RNase inhibitor were used in 
15 µL RT reactions for 30 min at 16°C, 30 min at 42°C, and 5 min at 85°C, using the 
TaqMan MicroRNA reverse transcription Kit (Applied Biosystems).  For real-time PCR, 
1.33 µL of cDNA, 0.2 mM TaqMan Probe, 1.5 mM forward primer, 0.7 mM reverse 
primer, and TaqMan Universal PCR Master Mix were added in 20 µL reactions for 10 
min at 95°C and 40 cycles of 15 sec at 95°C and 1 min at 60°C.  All real-time PCR 
experiments were done using an iCycler iQ system (Bio-Rad).  Primers were as follows: 
Site I Looped RT primer: 5’- GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC 
GCA CTG GAT ACG ACA CAG CG -3’; Site I Forward Primer:  5’- GCT GAT GAG 
CTC TTC GTC G - 3’; Site I Reverse Primer:  5’- GTG CAG GGT CCG AGG T - 3’; 
Site I probe primer: 5’- 6- FAM- TCG CAC TGG ATA CGA CAC AGC GAC GA –




5.2g Determination of HIV-1 tat/rev expression.  
Human PBMCs were obtained from treated mice at five and seven weeks post-
infection (one and three weeks post-injection) and total RNAs were isolated with STAT-
60 (TEL-TEST “B”) according to the manufacturer’s instructions.  Residual DNA was 
digested using the DNA-free kit per the manufacturer’s instructions (Ambion). cDNA 
was made using 2 µg of total RNA. Reverse transcription was carried out using Moloney 
murine leukemia virus reverse transcriptase and random primers in a 15 µL reaction 
according to the manufacturer’s instructions (Invitrogen).  Expression of the tat/rev 
coding RNAs was analyzed by quantitative RT-PCR using 2! iQ SyberGreen Mastermix 
(BIO-RAD) and specific primer sets at a final concentration of 400 nM. Gapdh 
expression was used for normalization of the qPCR data.  Primers were as follows: IIIB 
tat/rev forward primer: 5'- GGC GTT ACT CGA CAG AGG AG -3'; IIIB tat/rev reverse 
primer: 5'- TGC TTT GAT AGA GAA GCT TGA TG -3'; BaL tat/rev forward primer: 
5’- GAA GCA TCC AGG AAG TCA GC -3’; BaL tat/rev Reverse primer: 5’- TGC TTT 
GAT AGA GAA ACT TGA TGA -3’; gapdh forward primer 1: 5’- CAT TGA CCT 
CAA CTA CAT G-3’; gapdh reverse primer 2: 5’- TCT CCA TGG TGG TGA AGA C-
3’.  
  
5.2h 5’-RACE PCR assay to detect in vivo RNAi mediated target mRNA cleavage 
Total RNA was isolated from PBMCs of treated mice using STAT-60 as 
described above.  Residual DNA was digested using the DNA-free kit per the 
manufacturer’s instructions (Ambion).  Subsequently, total RNAs (5 µg) were ligated to a 
GeneRacer adaptor (Invitrogen) without prior treatment. Ligated RNA was reverse 


transcribed using a gene specific primer 1 (GSP-Rev 1: 5’- CCA CTT GCC ACC CAT 
CTT ATA GCA -3’) and SuperScript III reverse transcriptase according to the 
manufacturer’s instructions (Invitrogen).  To detect cleavage products, PCR and nested 
PCRs were performed using primers complementary to the RNA adaptor (5’-cDNA 
primer: 5’- GGA CAC TGA CAT GGA CTG AAG GAG TA -3’) and gene-specific 
primers (GSP-Rev 2: 5’- CCC AGA AGT TCC ACA ATC CTC GTT -3’; GSP-Rev 3: 
5’- TGG TAG CTG AAG AGG CAC AGG CTC -3’; GSP-Rev 4: 5’- CGC AGA TCG 
TCC CAG ATA AGT GCT AA -3’).  Amplification products were resolved by agarose 
gel electrophoresis and visualized by ethidium bromide staining.  The specific PCR 
products were recovered using a QIAquick Gel purification Kit and then were cloned into 
TOPO TA cloning vector pCR 2.1-TOPO vector (Invitrogen). Individual clones were 
identified by DNA sequencing. 
 
5.2i Interferon assays  
Total RNA was isolated from PBMCs of treated mice using STAT-60. Expression 
of mRNAs encoding p56(CDKL2) and OAS1 were analyzed by quantitative RT-PCR 
using 2! iQ SyberGreen Mastermix (BIO-RAD) as described above and specific primer 
sets for these genes at final concentrations of 400 nM.  Primers were as follows: P56 
(CDKL2) forward, 5’- TCA AGT ATG GCA AGG CTG TG -3’; P56 (CDKL2) reverse, 
5’- GAG GCT CTG CTT CTG CAT CT -3’; OAS1 forward, 5’ - ACC GTC TTG GAA 
CTG GTC AC -3’; OAS1 reverse, 5’- ATG TTC CTT GTT GGG TCA GC -3’; gapdh 
expression was used for normalization of the qPCR data. In addition, 25-50 µL of EDTA-
treated plasma was collected 2 and 24 hours post treatment. As a positive control for INF-


" induction, mice were injected with 5 µg of poly (I:C) (Sigma) intravenously in a 50 
µL volume. IFN-" levels were evaluated by Human IFN-"1 ELISA Ready-SET-Go! 
(eBioscience). 
 
5.2j Statistical Methods  
The mouse viral loads and CD4:CD3 T-cell ratios were plotted by using a lowess 
smoother across values.  Viral loads were first log-transformed prior to smoothing and 
then anti-transformed for plotting.  Missing values were imputed with a last observation 
carried forward scheme.   
To measure the differences between mouse treatment groups, we considered a 
primary endpoint evaluating longitudinal behavior over time. Our method was to 
calculate a cumulative area under the curve (AUC) for each mouse, and then compare 
aggregate mean AUCs between mouse groups. For any sequential time points, (xi, xj), 
and their corresponding endpoints, (yi, yj), the area under the curve was calculated by 
using the area of a trapezoid: 0.5 ! (xj – xi) ! (yi + yj). The cumulative AUC of a single 
observation for the duration of the experiment was the cumulative sum of trapezoids. 
 TheKruskal-Wallis rank sum ANOVA analog was used for the groupwise 
cumulativeAUC comparisons. We compared pairwise group mean AUCs using t-tests 
and exact permutation tests under the Hothorn and Hornik exactRankTests package for 
the R language (212-214). Details for deriving the permutation p-values in general are 






5.3a Anti-gp120 aptamer and aptamer-siRNA chimera (Ch A-1)inhibit CCR5 and 
CXCR4 tropic lab and clinical isolates in vitro 
We previously described the in vitro selection of gp 120 aptamers that bind the 
HIV-1 Bal 1 envelope with low nanomolar dissociation constants.  The lead aptamer, 
designated as A-1 was fused to an siRNA targeting the HIV-1 tat/rev encoding RNAs, 
and the chimeric construct Ch A-1 (Figure 5.1) delivered the siRNA to HIV-1 infected 
cells resulting in targeted RNAi mediated knockdown of tat/rev expression. In these 
Fig. 5.1 Schematic of anti-HIV-1 gp120 aptamer-siRNA chimera (Ch A-1). The aptamer and sense strand segment 
of the siRNAs contain nuclease-resistant 2-fluoro uridine triphosphate and 2-fluoro cytidine triphosphate. The 
aptamer portion of the chimera binds to gp120 protein, whereas the 27-mer Dicer substrate siRNA duplex is targeted 
to the HIV-1 tat/rev common exon. A linker (UU) between the aptamer and siRNA is indicated in green. 
 
studies the chimera Ch A-1 provided enhanced inhibition over the A-1 aptamer alone.   
Both the A-1 aptamer and Ch A-1 chimera were shown to be capable of inhibiting the 
replication of both  CXCR4 tropic (NL4-3 and IIIB) and CCR5 tropic (Bal1) strains of 


HIV-1 in cultured T-lymphocytes (CEM cells) and in peripheral blood mononuclear cells 
(PBMCs) (174).   
To better determine the range of envelope types the aptamer and aptamer chimera 
could recognize, we examined their in vitro inhibitory activities using several CXCR4 
tropic and CCR5 tropic laboratory and clinical isolates (Figure S5.1 A-F).  HIV-1 viral 
challenge assays were carried out in vitro using human PBMCs and CEM T-cells. Cells 
were infected with the HIV-1 isolates followed by addition of the A-1 or Ch A-1 
constructs to the culture media three days post infection and viral replication was 
monitored by p24 ELISA assays. The results of these viral replication assays show that 
the aptamer A-1 and Ch A-1 chimera are capable of inhibiting a variety of clinical and 
lab isolates of HIV-1 to varying degrees (Figure S5.1A-H).  Relative to treatment with 
the aptamer alone the Ch A-1 chimera proved better at inhibiting the two laboratory 
strains of HIV-1 (Figure S5.1E and F) as well as tat/rev expression (Figure S5.1G and H). 
 
5.3b Chimeric Ch A-1 aptamer-siRNA is stable in mouse serum 
In order to effectively use the chimeric aptamer in vivo, we   established that the 
2’ Fluoro backbone modified aptamer-siRNA chimera is resistant to rapid degradation by 
serum nucleases.  The 2’ Fluoro-modified Ch A-1 was incubated in 50% or 5% mouse 
serum for different lengths of time followed by denaturing polyacrylamide gel 
electrophoretic analyses and imaging of the transcripts. The serum incubations revealed 
that the 2’-Fluoro modified Ch A-1 was partially degraded during 24 hours of incubation 
in 50% serum but was stable out to 72 hours in 5% mouse serum (Figure S5.2).   Thus the 
RNAs should persist for several hours in mouse serum following in vivo injections. 


5.3c Aptamer and Aptamer-siRNA chimera Ch A-1 suppresses HIV-1 viral loads in 
viremic RAG-hu mice 
In order to evaluate the potential efficacy of the Ch A-1 chimeric aptamer in vivo, 
we chose to test its anti-viral efficacy in the humanized Rag2-/- c-/- (RAG-hu)  mouse 
model of HIV-1 infection (54, 56). RAG-hu
 
mice infected with HIV-1 NL4-3 became 
viremic by 3 weeks post infection with viral loads averaging 105 per mL, indicating an 
established infection. We first compared the anti-HIV-1 activity of the chimeric Ch A-1 
RNA versus using the tat/rev siRNA as an RNA injection control.  Six animals were 
given five weekly injections of 0.25 nmols Ch A-1 or tat/rev siRNA alone.  Plasma viral 
loads were monitored at various times to determine the treatment efficacies (Figure 5.2A 
and Table S5.1A).  A general pattern of decreased viral loads was seen in the majority of 
chimera Ch A-1 treated mice compared to the HIV-1 infected, untreated and siRNA 
treated controls, and this reached statistical significance with a rank sum P = 0.0029 
(Figure 5.2A, Table S5.3A). The viral loads were suppressed to below detectable levels 
in all the chimera treated mice within a week post treatment (week 5 as shown) and this 
marked viral suppression persisted throughout the treatment period in the majority of 
mice. Four out of six mice had undetectable viral loads even up to three weeks post-
treatment, indicating the sustained efficacy of the Ch A-1 chimera (Table S5.1A). 
However, while there was a marked suppression during first three weeks, there was viral 
rebound in two of the Ch A-1 treated mice, suggestive of the emergence of Ch A-1  


Fig. 5.2 Aptamer A-1 and chimera Ch A-1, but not a mutant chimera, suppress viral loads in HIV-1–infected 
RAG-hu mice. Mice were infected with HIV-1 at week 0, and 5 weeks later, weekly treatments were started. The 
treatment period is indicated by the yellow region. (A) Viral loads in uninfected mice (n = 2), untreated mice (n = 5), 
tat/rev siRNA only–treated mice (n = 6), and ChA-1–treated mice (n = 6). (B) In a separate experiment, viral loads in 
uninfected mice (n = 3), untreated mice (n = 3), A-1 aptamer–treated mice (n = 3), Ch A-1 chimera–treated mice (n = 
3), and mutantA-5 chimera–treated mice (n = 3). The viral RNA was detected through qRT-PCR as described in 
Materials and Methods. Thus, if there was no detectable viral RNA, we established this as a value of 1 (100) to allow 
for the use of logarithmic values on the y axis. P values for the effects of A-1 and Ch A-1 are indicated and were 
calculated as described in Materials and Methods. The data for individual mice are presented in fig. S6.3 and table 
S6.1. 
 
resistance. Importantly, even though these animals had high viral loads, their levels of T-
cells did not decline (Table S5.2A).  The “naked” anti-tat/rev siRNA treatment did not 
provide viral suppression beyond one week. 
To determine the relative anti-HIV contribution of the siRNA component of the 
Ch A-1 aptamer-siRNA chimera, additional groups of 3 viremic animals treated with 0.25 
nmols of the A-1 aptamer, the chimeric Ch A-1 molecule and a mutant aptamer-tat/rev 
siRNA chimera Ch A-5, as described in the Materials and Methods.  The A-5 aptamer 
portion of Ch A-5 has previously been shown to have poor affinity for gp120. Plasma 
viral loads were monitored to ascertain the efficacy of each treatment (Figure 5.2B). Viral 
loads were strongly suppressed in A-1 and Ch A-1 treated mice compared to the non-
treated group, reaching statistical significance (P = 0.0107). As expected, there was no 


notable viral suppression in the mice treated with the control, mutant aptamer-siRNA 
chimera Ch A-5 (Figure 5.2B and Table S5.1B).  The viral levels remained suppressed in 
all of the A-1 and Ch A-1 treated mice throughout the 3 week treatment period (weeks 6, 
7 and 8). In the aptamer treated animals, there was viral suppression during the 3 week 
treatment period followed by moderate suppression continuing for an additional 2 weeks. 
In contrast all of the Ch A-1 treated animals had undetectable viral loads at week 9, 
which is one week after the last injection (Figure 5.2B and Table S5.1B). The lower viral 
loads in the Ch A-1 treated animals persisted through week 12. In contrast, viral loads 
returned to pretreatment levels by week 11 in the animals treated with the A-1 aptamer 
alone. The enhanced duration of HIV-1 suppression afforded by the inclusion of the 
siRNA in Ch A-1 is statistically significant (p=0.04).  
To validate that the Ch A-1 delivered the anti-tat/rev siRNA to infected T-
lymphocytes, PBMCs were collected at one and three weeks during, and three weeks 
after the last treatment of the first set of animals (Figure 5.2A). Small RNAs were 
extracted and analyzed for the presence of the tat/rev siRNA by real-time Taqman qRT-
PCR assays (Figure 5.3A). The results of these analyses showed that the tat/rev siRNA 
was detectable in PBMCs from all of the Ch A-1 treated mice at weeks five and seven, 
and in three of the animals at week 12, which is three weeks after the last injection.  In 
contrast, no siRNAs were detected in the PBMCs of mice treated solely with tat/rev 
siRNA. We also assayed for the down-regulation of tat/rev gene expression in PBMCs of 
infected and treated mice using qRT-PCR. Our results showed a 75-90% reduction in the 
levels of tat/rev transcripts in chimera treated mice at both 1 and 3 weeks during the 




Fig. 5.3 The detection and function of tat/rev siRNA in PBMCs from treated RAG-hu mice. (A) Detection of the 
siRNA sequences in PBMCs during (weeks 5 and 7 after infection) and after (week 12) treatment with Ch A-1 and 
siRNA only, and in untreated mice and uninfected mice (animals from Fig. 6.2A). One minus RT control, J274 ("RT), 
also was set up. The synthetic 27- and 21-mer tat/rev siRNAs were used as positive controls. The background copy 
number of siRNA is <106 (gray area). Error bars indicate SD (n = 4 measurements per sample). Some of the error bars 
are not discernible in the graph because their relative percentage was less than 5%. (B) Expression of tat/rev gene 
transcripts at the first and third weeks of treatment (weeks 5 and 7 after infection) with Ch A-1 and siRNA only and in 
untreated and uninfected animals (animals from Fig. 6.2A). Gene expression was normalized to that of a representative 
HIV-1–infected untreated mouse. 
 
To confirm that the tat/rev siRNA was indeed functioning through the RNAi 
mechanism in vivo, a modified 5’-RACE (Rapid amplification of cDNA ends) PCR was 
performed on RNAs isolated from PBMCs of the second group of treated animals 
represented in Figure 2B.  It has been established that Ago2 mediates cleavage between 
bases 10 and 11 relative to the 5’ end of the siRNA guide strand (236,237). Thus the 
RACE PCR product sequence analyses should reveal a linker addition at the base 10 
nucleotides downstream from the 5’ end of the siRNA guide strand.  PCR bands of the 
predicted lengths were detected in the PBMC samples from mice treated with the chimera 
Ch A-1 following three nested PCR reactions (Figure 5.4A). No appropriately sized 



















































Fig. 5.4 5-RACE PCR analysis of in vivo tat/rev siRNA delivered by Ch A-1. (A) Nested PCR products were 
resolved in an agarose gel; specific siRNA-mediated RACE PCR cleavage mRNA products are marked by a red arrow. 
(B) DNA sequence analyses of cloned RACE PCR products. The positions of the two different siRNA-directed 




or from those treated with the mutant aptamer-siRNA chimera Ch A-5. The gel-purified 
bands of the predicted lengths were cloned and individual clones were characterized by 
DNA sequencing to verify the expected PCR products. Two different cleavage sites were 
found in the samples from the Ch A-1 treatment (Figure 5.4B). One cleavage takes place 
between positions 10 and 11 from the 5’ end of the siRNA antisense strand (Figure 5.4B). 
The second RACE product was displaced by two nucleotides along the mRNA 
suggesting a different Dicer product of the tat/rev siRNA, generating a guide strand   
shifted by two bases relative to the other cleavage product. In total, these data provide 
strong evidence that the chimera delivered siRNAs are processed intracellularly and are 
functionally incorporated into RISC, thus triggering sequence specific degradation of the 
HIV tat/rev target RNA. 
 
5.3d The anti-gp120 aptamer and chimeric aptamer-siRNA provide protection 
against HIV-1 mediated T-cell depletion 
A major characteristic of HIV-1 infection is helper CD4+ T-cell loss during the 
acute stage of infection followed by a return to a set point for several months/years with 
an eventual depletion leading to AIDS (238, 239). Therefore, prevention of CD4+ helper 
T-cell loss would contribute to immune reconstitution and restoration of immune 
function.  To determine whether treatment of HIV-1 infected RAG-hu mice with the Ch 
A-1 chimera could protect against depletion of CD4+ T-cells, CD4+ T-cell levels were 
evaluated in peripheral blood collected at weekly intervals during and post treatment 
(Figures 5.5, 5.6 and Tables S5.2A). In the first set of animals tested the protection 
against T-cell depletion was significant when we compared the non-treated group with 


the chimera A-1 group (P = 0.0476) (Figure 5.5A and Table S5.2A). In control, non-
infected mice (HIV negative) the levels of CD4+ T-cells remained relatively stable within 
a 5% variation range, whereas in untreated HIV-1 infected mice the CD4+ T-cell levels 
began to decline beginning at 4 weeks post infection to below 50% of the starting levels 
at 18 weeks post-infection.  In contrast, the levels of CD4+ T-cells in Ch A-1 treated 
mice remained at or near the levels of uninfected mice and this level remained stable well 
beyond the last treatment, indicating that the chimeric construct provides protection 
against CD4+ cell depletion. While the protection against T-cell depletion in the second 
group of animals is clearly discernable, due to the shorter time frame of A-1 and Ch A-1 
injections (3 weeks vs 5 weeks for the first group of animals) it approached, but did not 
reach statistical significance (P = 0.0920) (Figure 5.5B and Table S5.2B).  
Fig. 5.5 Protection of RAG-hu mice from CD4+ T cell loss by the Ch A-1 chimera. CD4+ T cell levels were 
assessed by FACS at each indicated week before and after siRNA treatment. BL, baseline measurement. Treatment 
duration is indicated by the yellow region. (A) Mice from the first experiment (shown in Fig. 6.2A) group. Uninfected 
mice (n = 2), untreated mice (n = 5), tat/rev siRNA–treated mice (n = 6), and chimera Ch A-1–treated mice (n = 6). 
(B) Mice from second experiment (shown in Fig. 6.2B). CD4-CD3 T cell ratios were assessed by FACS at each 
indicated week before and after treatment. P values for both experiments were determined as described in Materials 
and Methods. For baseline measurements, each individual mouse was bled twice before HIV-1 infection and the CD4-
CD3 values were averaged within treatment groups to establish a baseline CD4-CD3 level. The data for individual 
mice are presented in fig. S6.4 and table S6.2. 


Fig. 5.6 Effect of in vivo administration of Ch A-1 on type I IFN. (A) The effect of aptamer A-1 and chimera A-1 on 
expression of type I IFN response genes (p56 and OAS1) at week 7 after infection. IFN--treated, infected human 
PBMCs were used as a positive control. Gene expression was normalized to the gapdh mRNA. Error bars indicate SD 
(n =4). (B) Expression of IFN- 2 or 24 hours after RNA injection as measured by an ELISA. Poly I:C-treated, HIV-
infected RAG-hu mice were used as a positive control. Error bars indicate SD (n = 3). 
 
5.3e Anti-gp120 aptamer-siRNA chimera does not trigger type I interferon response 
in vivo 
It has been demonstrated that systemic administration of synthetic siRNA 
duplexes can activate innate immune responses, inducing cytokines such as tumor 
necrosis factor-alpha (TNF-"), interleukin-6 (IL-6), and interferons (IFNs), particularly 
IFN-alpha (IFN-") (215).  Such non-specific immune activation by siRNA-based drugs 
could contribute to the anti-viral effects but can also create undesirable toxicities. We 
therefore assessed the potential induction of type I IFN-regulated gene expression using 
quantitative RT-PCR expression assays on PBMC derived RNAs isolated from chimera 
treated and control mice (Figure 5.6A). We used IFN-" treated PBMCs as a positive 
control to compare up-regulation of p56 and OAS1 gene expression.  We did not observe 
type I IFN responses in PBMCs from any of the animals at different times post-treatment 
(Figure 5.6A). Using an ELISA assay we also directly monitored IFN-" levels in treated 


mice at 2 hours and 24 hours post-injection of the experimental RNAs (Figure 5.6B). 
Less than 1 ng/mL of IFN-"  was detected in one of the aptamer and two of the Ch A-1 
treated animals, but these levels are several folds lower than those induced by Poly I:C 
(Figure 5.6B). 
  
5.3f Deep sequence analyses of viral RNAs for envelope and tat/rev target mutations 
Development of viral resistance is a common setback with HIV-1 therapies due to 
generation of viral escape mutants. To assess the possible emergence of viral mutants in 
the HIV envelope and tat/rev sequences we carried out deep sequencing analyses of these 
two regions of the virus.  Our goal was to determine whether or not a specific class of 
mutations predominated in the samples from treated versus non-treated, HIV infected 
animals.  In order to have enough material to carry out these analyses we used pooled 
virus from serum collected from Ch A-1 treated animals at weeks 7 through 9 of the first 
set of experiments and compared this sample with virus collected from animals not 
receiving anti-viral treatment. Solexa deep sequence analyses of viral RNAs showed  a 
small increase in the percentage of point mutations in the envelope sequences of Ch A-1 
chimera treated animals relative to non-treated controls, but no dominant mutant(s). 
Figure S6.3 lists all the point mutations in the HIV-1 envelop domain with a frequency 
above 1%. More changes were detected in the gp120 domain (31 mutations) compared to 
the gp41 domain (5 mutations). There were only 7 mutations (less than 1%) in the tat/rev 
target sequence (Figure S5.3). These results suggest some selective pressure on the HIV-
1 gp120 envelope exerted by the aptamer. Nevertheless, even for this gene, the mutation 


frequency is less than 5% above the frequency observed in non-treated animals and most 
importantly, no dominant mutations were found.  
 
5.4 Discussion 
In the present study we have tested RNA based combinatorial approach for 
treatment of HIV-1 infection in a humanized mouse model that supports HIV-1 
replication and T-cell decline as a consequence of HIV-1 infection. Prior to our studies, 
single chain antibody-siRNA chimeras targeting either gp120 expressing cells or the T-
cell specific CD7 receptor  have been shown to functionally deliver anti-HIV-1 siRNAs 
in vivo (122).  However, in these studies only the siRNA component has been shown to 
have antiviral activity.  In contrast, we observe potent anti-viral activity by the aptamer 
itself, and this is enhanced by aptamer mediated delivery of an anti-HIV-1 delivered 
siRNA. 
The animal model we used for delivering the aptamer-siRNA chimera provides a 
very stringent and relevant test for anti-HIV-1 activity in human cells.  An advantage of 
this animal model versus non-human primates is that the humanized mice can be infected 
with any strain of HIV-1 that is capable of infecting humans whereas the non-human 
primate models require the use of SIV or SIV-HIV hybrid SHIVs.  Thus efficacious 
therapeutic approaches in the humanized mouse model do not have to be redesigned for 
human applications. In this system HIV-1 infection results in high levels of viral 
replication prior to the injection of the aptamer and Ch A-1 chimeric construct. The 
aptamer and aptamer-siRNA chimera decreased viral loads by several logs in all the 
treated animals within a week following intravenous administration. The suppression of 


viral load averaged three orders of magnitude or greater relative to controls and persisted 
throughout and beyond the treatment period in seven of nine animals tested in this study. 
The results presented in this study provide an in vivo validation of the anti-HIV-1 
efficacy of the anti-gp120 aptamer siRNA chimera.  We have used the aptamer both as an 
HIV neutralizing agent and as a vehicle for delivering a siRNA for triggering RNAi 
mediated down regulation of the HIV-1 tat/rev transcripts.  Using real time RT-PCR and 
RACE PCR assays we  demonstrated that the aptamer delivered siRNA is functionally 
active in vivo.  The combinatorial inhibitory functions of the aptamer and siRNA make 
this approach potentially superior to the other anti-siRNA delivery approaches reported 
prior to this work (122). In these other studies, only the siRNA was demonstrated to be 
functional as an anti-HIV agent.  The high potency and enhanced duration of viral 
suppression of the current approach is largely attributable to the dual anti-HIV activities 
of both the aptamer and aptamer delivered siRNA.  In contrast to the antibody mediated 
siRNA delivery, which requires biological production of the antibodies and creation of 
chimeric antibody-cationic peptide conjugates, the chimeric aptamer-siRNAs can be 
synthesized as a single unit or as two separate but combinable units using either 
biochemical or chemical methods. Since these RNA based molecules are not antigenic, 
they can be administered repeatedly without concerns about generating undue 
immunological responses expected with antibody-peptide conjugates. 
The aptamer-siRNA technology can be developed to avert viral resistance by the 
use of a cocktail of gp120 aptamers of different specificities that are combined with 
siRNAs directed against different mRNA targets (both viral and cellular). We envision 


that the first dual-function aptamer-siRNA chimeras can be applied to patients who 
harbor virus resistant to antiretroviral drugs.   
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The development of efficacious anti-HIV gene constructs has provided a 
promising approach for gene therapeutic strategies that restrict human immunodeficiency 
virus (HIV) infections and AIDS progression. CD34+ hematopoietic stem cells are an 
optimal choice to deliver such anti-HIV constructs into CD4+ HIV-1 susceptible cells, 
since they can be transduced with constructs prior to host engraftment.  Additionally, 
following implantation these cells will differentiate into the HIV-1 susceptible cells 
namely, macrophages, CD4 T cells and dendritic cells, which also possess an integrated 
anti-HIV defense. Lentiviral vectors provide the means of transduction, able to transduce 
non-dividing cells with the constructs of choice.   
For our studies we selected three previously developed and described anti-HIV 
gene constructs with different modes of action namely, small interfering RNAs (siRNAs), 
RNA decoys, and ribozymes. This triple combinatorial approach limits HIV mutant 
escape by targeting different steps of the viral infection cycle, much like current 
combinatorial anti-retroviral therapies. All three constructs were utilized in a lentiviral 
backbone to form a Triple-R construct, and our previous work has demonstrated the 
safety and efficacy of Triple-R vector-transduced CD34 cells in SCID-hu mice. Here we 
have expanded our previous work by hepatically injecting CD34 Triple-R vector-
transduced cells into RAG-hu mice, showing high levels of hematopoietic engraftment. 
This resulted in Triple-R transduced T cells and macrophage that resist HIV infection, 
effectively preventing CD4 T cell decline and efficiently developing an HIV resistant 
humanized mouse. These results illustrate the potential for gene therapy approaches in 




6.2 Materials and Methods: 
6.2a Combinatorial lentiviral vector design and production 
A third-generation HIV-derived lentiviral vector containing an EGFP reporter 
gene, HIV7-GFP, was used in this study as previously described (189). The construction 
of the combination Triple-R lentiviral vector along with the production of high-titer 
vectors was described previously (189). In brief, the shRNA component targeting rev/tat 
is placed under the control of a U6 promoter, whereas the TAR decoy is embedded in the 
U16 small nucleolar RNA backbone for nucleolar localization and is also driven by a U6 
promoter. The CCR5 ribozyme is under the control of an adenoviral VA1 promoter. 
Lentiviral vectors were generated in 293T cells. In all, 15g of the packaging construct, 
pCHGP-2, 15g of HIV7-GFP (control empty vector) or Triple-R (combination) transfer 
vector, 5g of vesicular stomatitis virus glycoprotein (pseudotyping envelope), and 5g 
of cytomegalovirus-Rev were transfected into cells cultured on 100-mm plates by 
calcium phosphate transfection. Vector supernatants were collected at 24, 36, 48, and 60 
hours after transfection and concentrated by ultracentrifugation. Vector titers were 
obtained by transduction of 293T cells and measured for EGFP expression by FACS. The 
titers were 3.8 ! 108 and 7.2 ! 108 transduction units for the HIV7-GFP control and 
Triple-R vectors, respectively. 
 
6.2b Isolation and transduction of CD34 HSCs 
CD34 HSCs were purified from human fetal liver using monoclonal antibody–
conjugated immunomagnetic beads (Miltenyi Biotech, Auburn, CA). The purity of CD34 


cells obtained was routinely >97% (data not shown). Cells were cultured in Iscove's 
medium containing 10% fetal bovine serum and 10 ng/ml of each of the cytokines IL-3, 
IL-6, and stem cell factor (SCF). For transductions, CD34 cells were incubated with the 
respective vectors (MOI 15), HIV7-GFP and Triple-R, overnight in the presence of 
8g/ml polybrene. Two rounds of transductions were performed on two consecutive 
days. Transduction efficiencies ranged from 74.9 to 92.4% for HIV7-GFP and Triple-R, 
respectively. 
 
6.2c Reconstitution of Rag-hu mice with transduced CD34+ cells 
To evaluate the capabilities of shRNA/TAR decoy/CCr5 ribozyme transduced 
CD34+ to develop hematopoietic cells, a Rag2-/-g-/- mouse model, that supports 
multilineage humatopoeisis was used.  Transduced CD34+ cells, 2 x 106 cells per mouse, 
were injected intrahepatically.  Eight weeks post-injection, peripheral blood was collected 
and analyzed for huCD45 and EGFP expression by FACS to evaluate reconstitution 
levels.  
 
6.2d Measurement of viral load in plasma 
To quantify cell-free HIV-1 by qRT-PCR, we extracted RNA from 25 to 50 ml of 
EDTA-treated plasma with the QIAamp Viral RNA kit (Qiagen). cDNAs were produced 
with SuperScript III reverse transcriptase (Invitrogen) with a primer set specific for the 
HIV-1 long terminal repeat (LTR) sequence, and qPCR was performed with the same 




6.2e Flow cytometry  
Whole blood was collected and red blood cells were lysed as reported (54). 
Peripheral blood cells were stained by hCD3-PE and hCD4- PECy5 (Caltag) antibodies 
and analyzed with a Coulter EPICS XL-MCL FACS analyzer (Beckman Coulter).For 
transgenic mice, CD4+ T cell levels were calculated as a ratio of the entire CD3 
population (CD4+CD3+-CD4"CD3+). Percent of transgene expression was determined 
on the EGFP+ of the CD3+-CD4+ population of cells.  
 
6.2f Multi-parametric FACS analysis of transgenic hematopoietic lineage 
To determine whether transgenic CD34+ cells differentiated in the Rag-hu mice, 
various cell surface markers were analyzed. Cells were stained with respective antibodies 
to CD3, a pan–T cell marker, CD4, and CD8 to detect sub-populations of T-helper, T-
cytotoxic, and immature double-positive cells, CD19 for B cell populations and CD14 for 
macrophages. The following antibodies were used for analysis: PE-Texas Red-CD3, 
Alexa Fluor 405-CD8 (Caltag, Burlingame, CA), PE-CY7-CD14, APC-CD45, PE-CD20, 
and PE-CY5-CD4 (BD Biosciences, San Jose, CA). Stained cells were analyzed on a 
Beckman Coulter ARIA flow cytometer. For evaluation of transgenic mice, cells 
expressing EGFP were analyzed. CD45-positive and EGFP-negative cells present in the 







6.2g Detection of transgene tat/rev siRNA expression 
The Rag-hu mice were engrafted with transgenic CD34 HECs as described. 
Thirty-two weeks later blood samples were collected, PBMCs extracted and small RNAs 
were isolated with MirVana miRNA isolation Kit (Applied Biosystems) according to the 
manufacturer’s instruction. The transgene siRNA quantification was performed using 
TaqMan MicroRNA Assay according to manufacturer’s recommended protocols 
(Applied Biosystems), as previously described (201). Briefly, ten nanograms of small 
RNA, 0.2 µM stem-loop RT primer, RT buffer, 0.25 mM each dNTP, 3.33 units/mL 
MultiScribe reverse transcriptase (RT) and 0.25 units/mL RNase inhibitor were used in 
15 µL RT reactions for 30 min at 16°C, 30 min at 42°C, and 5 min at 85°C, using the 
TaqMan MicroRNA reverse transcription Kit (Applied Biosystems). For real-time PCR, 
1.33 µL of cDNA, 0.2 mM TaqMan Probe, 1.5 mM forward primer, 0.7 mM reverse 
primer, and TaqMan Universal PCR Master Mix were added in 20 µL reactions for 10 
min at 95°C and 40 cycles of 15 sec at 95°C and 1 min at 60°C. 
 
6.3 Results 
6.3a Triple-R and HIV7-GFP vector-transduced CD34 cells can reconstitute Rag2-/-
c-/- mice  
CD34+ hematopoetic cells were isolated from fetal liver and transduced with 
either HIV7-green fluorescent protein (HIV7-GFP) or Triple-R vector. Levels of 
transduction efficiency were evaluated for EGFP expression by fluorescence-activated 
cell sorting (FACS) and were 74.9% and 92.4% for HIV7-GFP and Triple-R, respectively 


(Figure 6.1). A variation in transduction efficiency was observed but is consistent with 
what we have previously reported (193). 
Figure 6.1. Lentiviral vector transduction efficiency in CD34 cells. Purified CD34 cells were transduced with either 
control human immunodeficiency virus-7 green fluorescent protein (HIV7-GFP) or Triple-R vector and analyzed by 
fluorescence-activated cell sorting (FACS) for EGFP expression to determine transduction efficiency.  The percentage 
of EGFP-positive cells is indicated for each vector.  
 
Transgenic CD34+ cells were intra-hepatically injected into the Rag-/-g-/- 
(RAG-hu) mice which offer an ideal environment for hematopoiesis (55). Eight weeks 
post engraftment levels of reconstitution were determined by staining peripheral blood 
for the human pan leukocyte marker CD45 and for EGFP expression by FACS. Levels of 
total human engraftment (huCD45+) ranged from 10-66.4% for HIV7-GFP and 6.9-
72.5% for Triple-R transgenic mice (Table 6.1).  Transgene expression (EGFP) averaged 
52% and 49.25% for HIV7-GFP and Triple-R, respectively. Representative FACS plots 
for huCD45+ EGFP+ cells obtained from HIV7-GFP and Triple-R mice are shown 






6.3b Transgenic cell engraftment persists and results in normal hematopoietic 
differentiation 
To verify long term persisting cell engraftment and retained expression of transgenes, 
RAG-hu transgenic mice were monitored weekly for human leukocyte engraftment and 
EGFP expression (Figure 6.3a and 6.3b). A marked decrease in engraftment as compared 
to the non-manipulated mice is seen but is consistent with published data (216) (Figure 
3a).  Additionally, although engraftment mildly decreases over the 34 week study period, 
average engraftment persists over 30% and transgene expression remains stable for both 
treatment groups (Figure 6.3a and 6.3b). 
 
Table 6.1. Enhanced green fluorescent protein (EGFP) expression by leukocytes derived in RAG-hu mice. 
Vector-transduced CD34 cells were injected intra-hepatically into the RAG-hu mice and allowed to differentiate into 
leukocytes.  At 8 weeks post engraftment peripheral blood was collected and analyzed by FACS for the pan leukocyte 






Figure 6.2. Enhanced green fluorescent protein (EGFP) expression by leukocytes derived in RAG-hu mice. 
Vector-transduced CD34 cells were injected intra-hepatically into the RAG-hu mice and allowed to differentiate into 
leukocytes.  At 8 weeks post engraftment peripheral blood was collected and analyzed by FACS for the pan leukocyte 
marker huCD45 and EGFP expression.  Representative examples of a GFP and Triple-R mice are shown.. The 
percentages of huCD45-postive and EGFP-positive cells are indicated. 
Foreign transgenes can cause undesirable effects thus it is essential to evaluate 
transgenic cells to determine if they are physiologically normal.  Phenotypic analyses 
were performed to detect the normal differentiation of various hematopoietic cells.  The 
data shown are representative figures from all replicates analyzed.  As shown in Figure 
6.4, within a mouse, comparable levels of GFP+ and GFP- immune cells including T 
cells, B cells and macrophages were found in peripheral blood. This illustrates normal 
development of hematapoiesis from transgenic CD34+ stem cells.   


Figure 6.3. Transgenic huCD45 engraftment in Rag-hu mice.  A) Peripheral blood was collected and stained for 
huCD45 weekly to determine transgenic engraftment levels during the study period.  B) EGFP was analyzed using 
FACS analysis to determine transgenic percentage weekly.   
 
6.3c Triple-R vector-transduced CD34 reconstituted RAG-hu mice are resistant to 
HIV challenge and are completely protected against CD4 T cell depletion 
To determine the levels of viral inhibition conferred by Triple-R transduced 
CD34+ derived hematopoietic cells in Rag-hu mice, mice were challenged with R5-tropic 
BaL HIV-1 (3.4!106 i.u.) in a 100 µL volume injected intraperitoneally. Resistance to 
productive infection was observed with Triple-R transgenic mice compared to 
nontransduced and GFP-alone transgenic mice (Figure 6.5).  The lower viral loads in 
HIV7-GFP compared to the non-manipulated group reflects the lower engraftment levels 
and subsequent targets of HIV for high infection levels, however; a greater than a 1.2 log 
inhibition in Triple-R compared to control HIV7-GFP mice, which have similar levels of 
engraftment, was observed at all time points. These data suggest the resistance of Triple-
R transgenic mice to HIV-1 infection.   
The primary target of HIV-1 is CD4+ T cells, causing depletion of these cells to 
be a distinct characteristic of infection.  Loss of CD4+ T cells leads to AIDS, thus 
protection of these cells against HIV mediated depletion is a primary focus. To determine 


whether Triple-R transgenic mice were protected against CD4+ T cell depletion we 
measured cell levels of CD4 and CD3 in peripheral blood collected bi-weekly and 
expressed them as a T cell ratio (Figure 6.6a). HIV+ non-treated as well as HIV7-GFP 
animals had marked reduction in T cell levels (>20%) in contrast to the Triple-R mice 
which were completely protected against HIV mediated CD4+ depletion (Figure 6.6a).  
In control uninfected mice stable levels, with in a 5% variation range, were seen whereas 
in untreated HIV-1 and HIV7-GFP mice, the CD4+ T cell levels began to decline within 
2 weeks after HIV infection to below 50% and 60% of initial levels for HIV7-GFP and 
HIV+ non-treated control mice, respectively.  
To further verify the efficacy of protection by the Triple-R transgenes against 
CD4+ T cell depletion we analyzed EGFP expression in the CD4+ T cell population.  
Although lower transgene expression in CD4+ T cells by FACS analysis for EGFP was 
seen compared to transgene expression in CD45+cells in the same animals a stable 
expression rate remained even after HIV challenge in the Triple-R transgenic mice 




Figure 6.4. Multicolor FACS analysis of RAG-hu derived hematopoiesis. Whole blood was collected and stained 
with antibodies against CD3, CD4, CD14, CD 19, and CD45 and subjected to fluorescence-activated cell sorting 




Figure 6.5. Human immunodeficiency virus-1 (HIV-1) resistance by Triple-R transduced engrafted RAG-hu 
mice.  Vector-transduced CD34 cells were injected into the liver of irradiated RAG-hu pups and allowed to recapitulate 
hematopoiesis.  Mice were challenged with HIV-1 BaL at 14 weeks post engraftment.  Plasma collected from each 
mouse was subjected to q-RT-PCR for viral RNA levels.   
 
 
When the total CD4+ decline and the EGFP expression are taken together it is inferred 
that the transgenetic T cells in the HIV7-GFP mice decline at a similar or slightly faster 
rate than the non-transduced T cells in the same animals (Figure 6.6a and 6.6b).  The 
Triple-R transgenic cells and the non-transduced cells do not decline at all, illustrating a 





HIV-1 uses diverse mechanisms of pathogenesis to cause disease progression.  
Some of these include viral integration, a high mutation rate, viral latency, and the ability 
to evade the immune system in immunologically privileged sites.  In this regard, the use 
of combinatorial constructs targeting both pre-entry and post-integrations steps are more 







Figure 6.6. Triple-R protection against HIV-1 mediated CD4 depletion.  Mice engrafted with transduced CD34 cells 
were challenged with HIV-1 BaL at 16 weeks post engraftment and CD4 T cell levels were monitored.   Triple-R 
transduced CD4+ T cells are resistant to HIV-1 infection as can be seen by maintained CD4 levels compared to the non 







previous work has demonstrated the synergistic benefit of combined anti-HIV strategies 
into a single lentiviral vector in reducing the chances of generating viral escape mutants 
when compared to individual constructs.  
A number of recent studies have demonstrated the ability of RNAi and other HIV-
1 RNA inhibitory molecules to resist viral replication in vitro and in vivo.  Ribozymes, 
decoys, and shRNAs, to name a few, are potential effective antiviral RNA molecules.  
Utilizing different modes of action also limits potential competition with host machinery 
which could be detrimental to the cell.  Lentiviral vectors are ideal to deliver these anti-
HIV constructs into target cells as they are able to transduce nondividing cells, including 
hematopoietic stem cells which can derive into HIV-1 susceptible cells.  
Based on this concept, a Triple-R lentiviral vector construct was designed to 
target multiple stages of HIV’s life cycle. For entry into target cells during early infection 
HIV utilizes a chemokine coreceptor, CCR5, in conjunction with CD4. This derives a 
critical target for early HIV life cycle; as such a riboyzme under the control of an 
adenoviral VA1 promoter is utilized to down-regulate CCR5 expression.  After infection 
two essential regulatory proteins are produced by HIV-1. These two proteins, rev and tat, 
were also targeted by a shRNA under the control of a U6 Poly-III promoter that targets an 
overlapping ORF of both rev and tat transcripts. Tat is further targeted by a TAR decoy 
that acts to sequester tat and decrease transactivation of viral transcripts. Each of these 
expression cassettes were expressed under separate promoters and were previously shown 
to accumulate in high quantities.  As addressed above, using a combination of these anti-
HIV-1 transgenes in a single lentiviral vector offers a reduced chance of viral escape 
mutants.   


In the present study, the ability of this Triple-R lentiviral vector in transducing 
hematopoietic CD34+ stem cells was tested.  High efficient transduction of these cells 
was seen with transduction efficiencies at >70% with only two rounds of transductions.  
However, normal physiological development may be disrupted by off-target effects of 
transgene RNA inhibitory molecules.  To evaluate if phenotypically normal cells of the 
immune system develop from genetically modified HSCs we engrafted Rag-hu mice, 
which give an ideal environment for hematopoesis.  We show that cells of the 
hematopoietic lineage, including T cells, B cells and macrophages, dedifferentiate 
normally. 
To determine whether transduction of these three anti-HIV-1 transgenes conferred 
HIV-1 resistance, reconstituted mice were challenged with the macrophage tropic BaL 
HIV-1.  Both the non-treated and the GFP-alone transgenic mice showed high levels of 
infection based on qRT-PCR analysis of HIV viral loads in contrast to the Triple-R mice 
which had a several log fold reduction.  Additionally, protection of the primary target of 
HIV, CD4+ T cells, was seen in only the Triple-R transgenic mice.  Surprisingly, in these 
HIV-1 resistant mice, the non-transduced cells were also protected. This unexpected 
effect of bystander protection, which may be a result from the reduced viral load, should 
be further evaluated in future studies. These data taken together suggest the efficacy of 
the Triple-R construct to protect against HIV infection in vivo. With efficacy reported 










Without the advent of a vaccine the spread of HIV/AIDS continues to rise. With 
HAART therapy, slowed disease progression and extend patient’s lifespan occurs.  
However, with the relatively high cost of this treatment, toxic side effects, and drug 
resistance, new and innovative alternative therapies need to be developed. In this regard 
here we present several novel strategies for alternative or adjunct HAART therapy.   
In preventative therapeutic studies, we have shown that oral administration of 
clinically approved drugs namely, raltegravir or maraviroc, mediate complete protection 
against HIV-1 vaginal viral challenge in humanized mice, elaborating their potential 
utility as PrEPs.  These two compounds have different modes of action. Maraviroc is a 
low molecular weight CCR5 antagonist which inhibits the binding of the natural ligands 
of CCR5, namely chemokine ligand 3 (CCL3 also known as MIP-1), CCL4 (MIP1-) 
and CCL5 (RANTES) (195). It is a functional CCR5 antagonist devoid of agonist activity 
and shown to have a long lasting physical and functional occupancy of CCR5 leading to 
sustained antiviral activity. Topical vaginal application of maraviroc, as shown in chapter 
3, also is able to fully protect humanized mice from HIV-1 vaginal viral challenge. 
Raltegravir is an integrase strand transfer inhibitor that interferes with the viral DNA 
integration which is an essential step in viral replication. It is active against multidrug-
resistant and both CCR5-tropic and CXCR4-tropic HIV-1 strains. Topically applied 
formulations of Raltegravir are currently being evaluated for their protective applications 
and our preliminary data indicates successful application. However, being an 
interacellular acting compound, it appears that full protection is unattainable.   


The complexity of HIV illustrates the difficulties that have hindered the 
development of an effective vaccine. In this regard alternative approaches have become 
crucial in the attempts to curb the pandemic scale of HIV/AIDS. We have established that 
the RAG-hu mouse is suitable for studying HIV-1 pathogenesis, novel therapeutics and 
preventative methods. Our present results have provided the proof-of-concept data for 
further investigating  the potential of raltegravir and maraviroc as PrEPs thus identifying 
additional novel classes of molecules with different modes of action (194). Based on their 
proven broad spectrum of activity against divergent HIV strains in clinical situations, 
both these drugs make excellent candidates for PrEP. In this proof-of-concept study only 
one dose given sequentially for 7 days was tested and found to be efficacious in the 
prevention of HIV-1 infection.  
Synthetic vehicles such as dendrimers which can be synthesized with controlled 
and defined structures are amenable to chemical modification, stable in biological fluids 
and are not immunogenic. Importantly, an ideal siRNA delivery system for treatment of 
HIV-1 infection should have the capacity for combining siRNAs with different targets, 
both viral and cellular, to avert viral escape mutants. We have tested a PAMAM 
generation 5 dendrimer-dsiRNA delivery system for the treatment of HIV-1 infection 
both in cell culture and in a humanized mouse model.  
In work presented here we provided data demonstrating that a cocktail of three 
dsiRNAs targeting HIV-1 tat/rev and two cellular targets, CD4 and TNPO3 resulted in 
down-regulation of all three targeted transcripts in vivo. The inhibition of these targets 
resulted in a reduction of the viral RNA load and protection of CD4+ T cells from HIV-1 
mediated depletion. Furthermore the results of this study demonstrate that a combination 


of dsiRNAs can be functionally delivered to T-lymphocytes in vivo in the absence of any 
apparent toxicity. Importantly, we also showed that three months after we stopped the 
first treatments-allowing viral loads to become elevated again, animals could be re-
treated with the dendimer- cocktail dsiRNA, resulting once again in strong inhibition of 
HIV-1. Collectively, our results demonstrate the capacity of the G5 dendrimer delivered 
dsiRNAs to achieve marked viral suppression in vivo, resulting in protection of CD4 T 
cells from HIV-1 mediated depletion. Given the importance and challenge of siRNA 
delivery, it is of significance that our results provided the first demonstration of nano-
particle mediated delivery of siRNAs to hematopoietic cells in vivo, thus providing the 
impetus for further clinical development of this strategy.  
Single chain antibody-siRNA chimeras targeting either gp120 expressing cells or 
the T-cell specific CD7 receptor have been shown to functionally deliver anti-HIV-1 
siRNAs in vivo (116).  However, in these studies only the siRNA component has been 
shown to have antiviral activity.  As presented in chapter five we observed potent anti-
viral activity by the aptamer itself, and this is further enhanced by aptamer mediated 
delivery of an anti-HIV-1 delivered siRNA. The aptamer and aptamer-siRNA chimera 
decreased viral loads in HIV-1 infected humanized mice, by several logs in all the treated 
animals within a week following intravenous administration. The suppression of viral 
load averaged three orders of magnitude or greater relative to controls and persisted 
throughout and beyond the treatment period in seven of nine animals tested in this study. 
The results presented in this study provide an in vivo validation of the anti-HIV-1 
efficacy of the anti-gp120 aptamer siRNA chimera.  We have used the aptamer both as an 
HIV neutralizing agent and as a vehicle for delivering a siRNA for triggering RNAi 


mediated down regulation of the HIV-1 tat/rev transcripts.  The combinatorial inhibitory 
functions of the aptamer and siRNA make this approach potentially superior to the other 
anti-siRNA delivery approaches reported prior to this work (122). The high potency and 
enhanced duration of viral suppression of the current approach is largely attributable to 
the dual anti-HIV activities of both the aptamer and aptamer delivered siRNA.  Since 
these RNA based molecules are not antigenic, they can be administered repeatedly 
without concerns about generating undue immunological responses. 
A Triple-R lentiviral vector construct was designed to target multiple stages of 
HIV’s life cycle. Included in this construct are a ribozyme utilized to down-regulate 
CCR5 expression, a tat/rev shRNA and a TAR decoy. Using a combination of these anti-
HIV transgenes in a single lentiviral vector offers a reduced chance of viral escape 
mutants.   
In the present study, the ability of this Triple-R lentiviral vector in transducing 
hematopoietic CD34+ stem cells was tested.  Highly efficient transduction of these cells 
was seen with transduction efficiencies at >70% with only two rounds of transductions.  
We show that cells of the hematopoietic lineage, including T cells, B cells and 
macrophages, differentiate normally. 
To determine whether transduction of these three anti-HIV-1 transgenes conferred 
HIV-1 resistance, reconstituted mice were challenged with the macrophage tropic BaL 
HIV-1.  Both the non-treated and the GFP-alone transgenic mice showed high levels of 
infection based on qRT-PCR analysis of HIV viral loads in contrast to the Triple-R mice 
which had a several fold reduction.  Additionally, protection of the primary target of 
HIV, CD4+ T cells, was seen in only the Triple-R transgenic mice.  Surprisingly, in these 


HIV-1 resistant mice, the non-transduced cells were also protected. This unexpected 
effect of bystander protection should be further evaluated in future studies. These data 
taken together suggest the efficacy of the Triple-R construct to protect against HIV 
infection in vivo. 
All of the studies reported here were conducted in the RAG-hu mouse model, 
illustrating the utility of this model for HIV-1 preventative and therapeutic research. In 
this regard, humanized mice are likely to fill the gap for deriving preliminary data and in 
laying the ground work for subsequent macaque studies. Since HIV-1 itself can be used 
as a challenge virus, various drug resistant mutants that exist in the field can also be 
evaluated against different combinations of potential promising compounds. Now it is 
possible to conduct large scale in vivo preliminary screenings of a large number of 
potential microbicides, PrEP compounds, siRNA delivery vehicles, and gene therapy 
strategies in a cost effective manner.   
 
7.2 Future considerations 
Future studies of microbicides and other PrEPs should evaluate variations in the 
dose, timings of drug administration prior to vaginal challenge and duration of efficacy 
without further dosing after viral challenge to determine the memory effect. Additionally, 
drugs with a similar mechanism may be examined in the future for their likely similar 
protection. It is also necessary that field and drug resistant viruses be tested in this 
humanized mouse model. Furthermore, use of more than one drug in any PrEP will be 
more effective in field conditions. This can also be tested in this mouse model using a 


combination of raltegravir and maraviroc to derive pre-clinical data. Such evaluations 
will fine tune the PrEP regimens to be more practically applicable for clinical testing.  
With regards to siRNA therapeutics our data here supports future use of 
combinatorial multi-targeting dsiRNAs for treating HIV-1 infection as a stand alone 
therapy or as an adjnct to HAART therapy. Additionally, the aptamer-siRNA technology 
can be developed to avert viral resistance by the use of a cocktail of gp120 aptamers of 
different specificities that are combined with siRNAs directed against different mRNA 
targets (both viral and cellular). We envision that the first dual-function aptamer-siRNA 
chimeras can be applied to patients who harbor virus resistant to antiretroviral drugs.   
Although we present successful development of an anti-HIV-1 transgenic mouse 
many questions remain, particularly with assessing normal function of the immune cells 
after transduction, the prolonged effects of introduced endogenously expressed miRNAs 
and required transduced engraftment efficiency for viral suppression and T cell 
protection. Additionally, here we used a combinatorial approach but to limit potential 
adverse side effects and for their efficacy it would be beneficial to analyze each of the 
three constructs individually.  
The work presented throughout this dissertation was done in a preclinical setting 
utilizing the humanized mouse. In this regard an ultimate goal for these data presented is 
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Figure S4.2: Dendrimer-siRNA nanoparticles efficiently release siRNA and mediate specific gene silencing via the 
RNAi pathway in vitro.  qRT-PCR analysis indicated that G
5
-siRNA complexes (at an N/P ratio of 5) efficiently 
knocked down target TNPO3 gene expression in cultured CEM T-cells. G
5
-27 mer anti-TNPO siRNA complexes 
showed better efficacy than the G
5




Figure S4.3 Northern blot analyses demonstrate that the 27-mer Dicer substrate siRNA was efficiently delivered to 
CEM cells and was processed by Dicer into 21-23 mer siRNA.  
 
 
Figure S4.4 5’-RACE PCR analysis. mRNA from CEM cells treated with the G
5
-27-mer TNPO3 siRNA complexes 
was ligated to an RNA adaptor and reverse transcribed using a gene-specific primer. Depicted is an agarose gel 
electorphoresis of the 5’-RACE-PCR amplification products using a primer specific to the RNA adaptor and a reverse 




Figure S4.5: Dendrimer-mediated dsiRNA delivery system does not trigger type I interferon responses in cultured 
HIV-1 infected (a) CEM cells and (b) human PBMCs. IFN- treated HIV-1 infected human PBMCs were used as a 
positive control. Gene expression was normalized with the GAPDH mRNA. Error bars indicate SD (n = 3). The 
dendrimer-dsiRNA complexes did not induce cellular toxicity in (c) CEM cells and (d) human PBMCs under the 





Figure S4.6: Dendrimer-dsiRNA complexes suppress viral loads in HIV-1 infected RAG-hu mice while 
dendrimer alone has no affect on viral loads. HIV-1 viral loads were monitored at for several weeks post infection as 
indicated. The beginning and end of the treatment period is indicated by the yellow framed in region. Viral loads at 
each indicated week pre- and post-treatment and the time point of treatment start and end are indicated. The first-
treatment included five weekly injections: The viral loads of uninfected mice (n = 2), non-treated mice (n = 7), naked 
cocktail dsiRNA treated mice (n = 5), G5-mutant-tat/rev dsiRNA complex treated mice (n = 3), G5-tat/rev dsiRNA 





Figure S5.1: HIV-1 suppression by Aptamer A-1 and Aptamer-siRNA Ch A-1 chimera. (A-D) A-1 aptamer inhibition 
of HIV-1 in PBMCs(A) HIV-1 NL4.3, (B) HIV-1 92UG021, (C) HIV-1 RU570 and (D) HIV-1 98CN009. Inhibition of 
HIV-1 replication by the Aptamer A-1, Ch A-1 RNA and naked siRNA in (E) CEM cells infected with HIV-IIIB and in 
(F) PBMCs infected with BaL. Down regulation of tat/rev mRNA mediated by the aptamer delivered siRNA in (G) 




Figure S5.2: Stability of 2’-Fluoro modified chimeric RNA in mouse serum. RNA duplexes were incubated in mouse 
serum for the lengths of time indicated and were resolved by 8% PAGE. Stability of the Ch A-1 chimeric construct was 
evaluated following incubation in 50% or 5% mouse sera. 
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